This is the first report of the successful treatment of a serious case of feline infectious peritonitis (FIP) with Lianhuaqingwen Capsule (LH), a Chinese natural products medicine that has also been used to treat Covid-19. The one-year-old cat was diagnosed with FIP - strong ascites, aphasia, inflammation, difficulty breathing and weight loss. After 22 days of treatment with LH capsules, all signs of the cat returned to normal and the ascites gradually disappeared. This case report is the first description of the clinical recovery of a cat with systemic FCoV infection using LH capsules.
Feline coronavirus (FCoV), RNA alpha coronavirus, is a highly infectious enteric virus that is epidemiologically a member of the Coronaviridae family of the Nidovirales family. [1,2], and can infect cats of all ages. Most cases occur in cats aged 1-2 years and older than 11 years. May lurk in the intestines for a long time and cause feline infectious peritonitis (FIP) in a weakened immune or stress state [3], which is known to cats as an "incurable disease" with almost 100% mortality.
Although treatment of FIP with new therapies has been published [4], further investigation is needed into the efficacy and safety of FCoV-targeted broad-spectrum antiviral drugs. GS441524 is a great promise in the treatment of cats with FIP [5], but is not currently FDA approved. What's more, the cost of FIP treatment costs $ 5,000 to $ 9,000, which is a big financial burden for most ordinary families. The LH capsule, one of the natural products of TCM (Traditional Chinese Medicine), was made to inhibit SARS-CoV-2 replication. [6]. The LH capsule exerts its anti-influenza activity by regulating the immune response in order to influence both viral and host responses. [7]. The LH capsule was approved by the National Board of Health for Covid-19, a prospective randomized study involving 284 patients conducted in a multicenter environment suggests that treatment with LH capsules for 14 days significantly improved the rate of symptom relief. [8].
Case Study
"Big Tangerine" is a one-year-old neutered Chinese domestic cat (Felis catus) from a household of four cats (2 Felis catus, 2 British Shorthair). "Big Tangerine" developed an appetite loss and weight loss lasting several weeks. The other cats showed no signs of disease. On November 15, 2020, the cat was transferred to Guaiguai Pet Hospital (Tianjin, China). Abdominocentesis showed a large amount of ascites. FCoV was detected by RT-PCR in ascites and was thus diagnosed with FIP. Symptoms included aphasia (inability to swallow), diarrhea, ascites, lethargy, weight loss and difficulty breathing (Figure 1)
Figure 1: Cat body weight before, during and after recovery from FIP and timeline. Graphically represented cat weight: Day 0 represents the FIP diagnosis at the clinic. LH treatment was performed between 10 and 31 days. The cat lost 1.5 kg of weight during LH treatment (days 1 to 15). After the body returned to normal, the cat's weight increased rapidly and increased steadily even after the end of treatment, until it stabilized at about 7.2 kg.
RT-PCR of ascites showed a high FCoV load (Ct value 21.73). Laboratory test results showed elevated levels of white blood cells (WBC) and neutrophilic granulocytes (Neu), indicating severe inflammation (Table 1). In addition, the immune response was altered: lymphocyte levels (Lym%) were significantly reduced, indicating virus-induced lymphocyte depletion. SAA (marker of inflammation and tissue damage) was tested for cat diarrhea and respiratory distress (Fig. 2A). The patient received saline and protein as supportive care. Due to the clinical condition, the veterinarian recommended euthanasia or the experimental drug GS-441524 for the cat. Due to the high cost of GS-441524 treatment, cat owners decided to look for other therapy options.
Title
Day 0
Day 30
Reference range
Units
Leukocytes (WBC)
44.8
13.85
5.5-19.5
10 ^ 9 / L
Neutrophilic granulocytes (Neu%)
94.1
76.2
38-80
%
Lymphocytes (Lym%)
2.2
17.2
12-45
%
Monocytes (Mon%)
2.3
2.6
1.00-8.00
%
Eosinophils (Eos%)
1.4
3.9
1.00-11.00
%
Basophils (Bas%)
0
0.1
0.00-1.20
%
Neutrophilic granulocytes (Neu#)
42.16
10.56
3.12-12.58
10 ^ 9 / L
Lymphocytes (LYM#)
0.98
2.38
0.73-7.86
10 ^ 9 / L
Monocytes (Mon#)
1.04
0.36
0.07-1.36
10 ^ 9 / L
Eosinophils (Eos#)
0.62
0.54
0.06-1.93
10 ^ 9 / L
Basophils (Bas#)
0
0.01
0.00-0.12
10 ^ 9 / L
Erythrocytes (RBC)
5.83
7.23
4.62-10.20
10 ^ 12 / L
Hemoglobin (HGB)
85
117
85.0-153.0
g / L
Hematocrit
24.8
34.6
26.00-47.00
%
Mean erythrocyte volume (MCV)
42.5
47.9
38.00-54.00
fL
Mean erythrocyte hemoglobin (MCH)
14.6
16.1
11.89-18.00
pg
Mean erythrocyte hemoglobin (MCHC) concentration
342
337
290.0-360.0
g / L
Erythrocyte distribution width - coefficient of variation (RDW-CV)
20.6
16
6.50-23.00
%
Erythrocyte distribution width - standard deviation (RDW-SD)
40.5
35.5
19.30-43.10
fL
Platelets (PLT)
187
333
100.0-518.0
10 ^ 9 / L
Mean platelet volume (MPV)
11
11.7
9.90-16.30
fL
Platelet distribution width (PDW)
10.2
14.7
12.00-17.50
Platelet hematocrit (PTC)
0.21
0.39
0.09-0.70
%
Table 1. Laboratory data related to FIP treatment monitoring
The cat's caregiver sought help in traditional Chinese medicine. Due to feline coronavirus infection and respiratory distress, he was recommended an LH capsule, which was prescribed for the treatment of respiratory diseases and approved by the National Animal Health Commission for the treatment of covid-19. FCoV and SARS-CoV-2 share partially identical RNA sequences, so antivirals targeting SARS-CoV-2 are likely to be effective against FCoV as well.
Figure 2. A, B, C. The SAA value on day 0 is 21.93 mg / l <0.5 mg / l on day 30. D, Abdominal swelling and ascites on day 0. E, ascites disappeared on day 21.
On 17 November 2020, 'Big Tangerine' began receiving 4 LH capsules (Table 2) three capsules a day (0.35 g per capsule) in combination with antipyretics; no side effects were observed. Shortly afterwards (November 18, day 1), shortness of breath improved. At that time, he received a liquid diet for his ongoing anorexia and diarrhea. 48 hours after taking the drug (November 19, day 2), the patient's condition was largely stabilized and the first soft stool appeared; his mental condition also improved. He was able to sit up, lick his fur while he was still lying on the ground a few days ago, gasping for breath. 3 days after starting treatment (November 20), he started eating on his own (albeit in small amounts). During the next 7 days of treatment, his appetite improved and the effusion began to decrease. During this time he had soft stools. In early December, the cat underwent a palpation examination, which showed that the effusion had almost completely disappeared. As shown in Figure 1, with ascites disappearing, it was estimated to be about 1.5 kg lighter, which was the lowest weight throughout the treatment. On December 2, all symptoms subsided. The cat started running and playing with the other cats.
Ingredient
Component
%
Forsythia suspensa (Zlatovka overhang)
Dried fruit
12.7
Lonicera japonica (Japanese earthworm)
Dried flower bud or flower
12.7
Ephedra sinica (Chinese wormwood)
Dried herb stem
4.2
Isatis indigotica (Boryt dyeing)
Dried root
12.7
Pogostemon cablin (Patchouli)
Dried above ground part
4.2
Rheum palmatum (Rhubarb
Dried root and rhizome
2.5
Glycyrrhiza uralensis (Ural Malt)
Dried root and rhizome
4.2
Dryopteris crassirhizoma
Dried rhizomes and leaves
12.7
Rhodiola crenulata (Rozchodnica)
Dried root and rhizome
4.2
Houttuynia cordata (Hutinia)
Dried above ground part
12.7
Prunus sibirica (Siberian apricot)
Dried ripe seed
4.2
gypsum
CaSO4 · 2H2O
12.7
1-menthol
C10H20O
0.4
Table 2. Capsule composition (granules) Lianhuaqingwen * LH capsules have been manufactured according to the Pharmacopoeia of the People's Republic of China.
Result and next steps
The patient continued to take LH capsules every day until December 9. The treatment period lasted 3 weeks and the symptoms did not return after discontinuation of the drug. On January 3, he was examined at a pet clinic in Guaiguai and his blood count and SAA levels were already in the normal range, except for total protein (8.2 g / dl, normally 5.4 to 8.2) and urea (42 mg / dl, normally 10-30). (Table 3 and Figure 2). The samples were subsequently tested by FCoV RT-PCR with a negative result, which means that the FCoV viral load was below the limit of detection. The symptoms of the FIP did not recur until the report was submitted (March 17).
Title
Day 30
Reference range
Units
ALB albumin
4
2.2-4.0
g / dL
Alkaline phosphatase ALP
38
10-90
U / L
Alanine aminotransferase ALT
60
20-100
U / L
AMY amylase
1082
300-1100
U / L
Total bilirubin TBIL
0.5
0.1-0.6
mg / dL
Urea BUN
42
10.0-30.0
mg / dL
Calcium CA
11.7
8.0-11.8
mg / dL
Phosphorus PHOS
4.5
3.4-8.5
mg / dL
Creatinine CRE
1.5
0.3-2.1
mg / dL
Glucose GLU
101
70-150
mg / dL
NA +
146
142-164
mmol / L
K +
4
3.7-5.8
mmol / L
Total TP protein
8.2
5.4-8.2
g / dL
GLOB globulin
4.2
1.5-5.7
g / dL
Table 3: Laboratory values after FIP treatment
Discussion
FIP is a fatal disease in cats caused by FCoV, which lurks in the intestinal system. FIP is still a terminal disease with a variable death time, with more than 95% feline cats dying several days to months after diagnosis [9]. The symptoms of FIP in cats take two forms: dry and moist[10]. The most prominent symptom of wet FIP is effusion in the abdomen and thoracic cavity [11]. Glucocorticoids such as prednisolone are used to relieve symptoms. After diagnosing FIP ascites, a veterinarian may recommend euthanasia because there are few cases of successful treatment.
There are currently several effective therapies. For example, the successful treatment of FIP with GS441524 has recently been published [12], GC376 [13] or an oral adenosine nucleoside analog [14]. GS441524 in combination with antibiotic treatment, recommended by many veterinarians, has shown a good therapeutic effect. GS441524 is a precursor of remdesivir used in the treatment of COVID-19. GS441524 treatment lasts for 1-3 months, which can mean approximately $ 5,000 to $ 9,000 in China. Unfortunately, due to price and availability (GS441524 not yet officially approved), many cat owners are giving up this proven and effective treatment option.
In this case, the veterinarian feared that without the use of GS441524, the cat would not survive even a week. Cat owners hoped to find another therapy. LH Capsule, a Chinese patent drug composed of 13 herbs, is a commonly used broad-spectrum antiviral drug developed on the example of traditional Chinese medicine [15]. It is used to treat a series of influenza viruses, such as viral rhinitis, pneumonia and the like. [16, 17] Pharmacological and clinical studies have shown that it can significantly alleviate the inflammatory response by inhibiting viral replication and reducing the release of cytokines from host cells. [17]. It is also recommended as one of the supportive drugs in the treatment of COVID-19 [6, 18, 19]. Therefore, we tried to use this drug to alleviate the inflammatory response and symptoms caused by FIP. Surprisingly, there was a significant daily improvement during the first week of treatment. Therefore, we have recorded this case in detail for scientific purposes.
Several strengths of this case study need to be mentioned. First, it is a cheap and readily available drug for cat owners, which can benefit more cats. Especially in China, where the pet population has risen sharply in the last decade, while current pet clinics do not have sufficient capacity to meet the medical care needs of pets. Many pets have to face euthanasia because their owners cannot afford expensive drugs. Second, LH will take effect within a week and the FIP will heal in about a month, while the recommended duration of administration of GS-441524 is 84 days.
Although the decision to administer LH was based on the worsening of the cat's clinical condition and the optimistic results achieved with LH use, we should handle it with caution. Further studies are needed to determine the safety and efficacy of LH in the treatment of feline feline infections. Notably, although the samples were negative for FCoV, the TP and BUN values were slightly higher than normal. We cannot yet be sure whether the cause was LH capsules or a virus. Previous clinical studies have not shown whether the LH capsule has side effects causing liver damage in humans. Clearly, further research and data on BUN levels are needed in future cases. In order to find out whether this was not just an isolated case, 3 other cats also underwent experimental treatment and all of them recovered after about a month. Due to incomplete test data for some cats, we were only able to list them in supplementary materials.
Conclusions
To our knowledge, this is the first use of natural products to reverse (or cure) a cat with FIP. A study with multiple cats undergoing this treatment protocol is required.
Abbreviations
FCoV: feline coronavirus; FIP: Infectious feline peritonitis LH capsule: Lianhuaqingwen capsule TCM: Traditional Chinese Medicine
References
Pedersen NC, Sato R, Foley JE, Poland AM. Common virus infections in cats, before and after being placed in shelters, with emphasis on feline enteric coronavirus. Journal of feline medicine and surgery. 2004;6(2):83-88.
Felten S, Hartmann K. Diagnosis of Feline Infectious Peritonitis: A Review of the Current Literature. Viruses. 2019;11(11).
Rissi DR. A retrospective study of the neuropathology and diagnosis of naturally occurring feline infectious peritonitis. Journal of veterinary diagnostic investigation: official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc. 2018;30(3):392-399.
Kim Y, Shivanna V, Narayanan S, et al. Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses. Journal of virology. 2015;89(9):4942-4950.
Ko WC, Rolain JM, Lee NY, et al. Arguments in favor of remdesivir for treating SARS-CoV-2 infections. International journal of antimicrobial agents. 2020;55(4):105933.
Runfeng L, Yunlong H, Jicheng H, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacological research. 2020;156:104761.
Zhang ZJ, Morris-Natschke SL, Cheng YY, Lee KH, Li RT. Development of anti-influenza agents from natural products. Medicinal research reviews. 2020;40(6):2290-2338.
Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine: international journal of phytotherapy and phytopharmacology. 2020:153242.
Dickinson PJ, Bannasch M, Thomasy SM, et al. Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis. Journal of veterinary internal medicine. 2020;34(4):1587-1593.
Hartmann K. Feline infectious peritonitis. The Veterinary clinics of North America Small animal practice. 2005; 35 (1): 39-79, vi.
Giori L, Giordano A, Giudice C, Grieco V, Paltrinieri S. Performances of different diagnostic tests for feline infectious peritonitis in challenging clinical cases. The Journal of small animal practice. 2011;52(3):152-157.
Pedersen NC, Perron M, Bannasch M, et al. Efficacy and safety of the nucleoside analog GS-441524 for the treatment of cats with naturally occurring feline infectious peritonitis. Journal of feline medicine and surgery. 2019;21(4):271-281.
Pedersen NC, Kim Y, Liu H, et al. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. Journal of feline medicine and surgery. 2018;20(4):378-392.
Sharun K, Tiwari R, Dhama K. Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis. Annals of medicine and surgery (2012). 2021;61:122-125.
Addie DD, Curran S, Bellini F, et al. Oral Mutian®X stopped faecal feline coronavirus shedding by naturally infected cats. Research in veterinary science. 2020;130:222-229.
Ding Y, Zeng L, Li R, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC complementary and alternative medicine. 2017;17(1):130.
Liu L, Shi F, Tu P, et al. Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19. Medicine. 2021; 100 (4): e24475.
Duan ZP, Jia ZH, Zhang J, et al. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chinese medical journal. 2011;124(18):2925-2933.
Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacological research. 2020;155:104743.
Introduction - Pregnancy is an interesting immunological paradox. Although organs and tissues from individuals of the same (allograft) or other species (xenograft) are considered foreign and destroyed, this is not the case for a fetus that is an allograft. The prevention of fetal rejection is accompanied by events related to the forthcoming complex hormonal changes. 1-4 The effects of pregnancy affect many functions of the immune system. 1-4 However, pregnancy has the main effect on T cell immunity. T-cell immunity is mediated by a class of thymus-affected lymphocytes that are active in identifying infected host cells evaluated as foreign due to their interaction with pathogens. T-cell immunity also plays an important role in autoimmune diseases.
The modulation of immunity that occurs during pregnancy can variously affect maternal immunocompetence. Pregnancy is known to ameliorate or exacerbate autoimmune diseases, increase the postpartum incidence of autoimmune diseases, and increase susceptibility to many common bacterial, fungal, and viral diseases. 4-7 The incidence of these diseases is greatest in the third trimester, when estradiol and progesterone levels are highest in the blood.4
Although mothers may be more susceptible to certain infections during pregnancy, the fetus remains protected from maternal infections through a placental barrier that separates the mother's and fetus's bloodstream. Although this barrier is highly effective in retaining infectious agents, it is permeable to most drugs. Therefore, the role of the placental barrier in resisting mainly pathogens differs from the blood-brain barrier, which is a barrier for both drugs and pathogens.
FIP and pregnancy - Only limited information has been published on FIP in pregnant females. 8-10 Based on the author's further experience with the small number of cases observed during FIP treatment with GS-441524, the affected females appear to be in the subclinical or preclinical stage of FIP at the time of pregnancy. The immunosuppressive effect of pregnancy then allows the infection to progress to a clinical stage, usually in the last trimester. The most common clinical form of FIP in pregnant cats is abdominal and moist, and clinical signs usually appear in the late stages of pregnancy, at or shortly thereafter.
FIP in females also affects kittens, depending on the severity of the infection and its timing. Kittens either die at the beginning of pregnancy when they are resorbed, aborted at a later stage of pregnancy, or they may be born sick and die soon after birth. 8-10 Some may even survive for weeks before succumbing to FIP. However, some litters are born alive and remain healthy during foster care or bottle feeding. It is not clear what role infection plays in this mortality. Are early fetal resorptions and abortions due to fetal infection from maternal monocytes / macrophages? Are fetal deaths caused by the non-specific effect of the disease and the associated cytokine storm? It is likely to be a combination of both. However, there is no doubt that some kittens may be infected in late pregnancy, be relatively healthy and may develop confirmed FIP in the first weeks of life.
The advent of FIP treatment with GS-441524 significantly affected FIP during pregnancy, the fate of fetuses and newborn kittens. Females treated in the early stages of the disease often give birth to healthy kittens, and if they respond quickly to treatment, they can take care of them in the usual way. No studies have been performed to determine how much GS-441524 reaches the fetus from the mother's bloodstream, but it is a small molecule and should easily cross the placental barrier. GS-441524 has been shown to have no adverse effects on fetal or kitten development when administered to a female during the second or third trimester and / or during the neonatal period. GS-441524 is thought to pass easily from females to kittens in colostrum and milk.
The current recommendation is to treat pregnant females as if they were not pregnant and not to interfere with pregnancy or neonatal care unless necessary. Successive ultrasound examinations will provide an accurate picture of what is happening to the fetus. Some will be dead and absorbed in utero, others are weak and miscarried, others have a normal appearance and are healthy after birth. Females usually respond quickly to GS-441524 and most of them are healthy enough to care for and care for their kittens. In addition to the treatment itself, females should be allowed to interact normally with their kittens. Kittens do not need individual treatment, as a sufficient amount of GS-441524 is probably provided by breast milk. Kittens that are born healthy and not breastfed can be artificially fed and their weight monitored daily. GS-441524 treatment should only be used if a lack of weight gain and activity indicate that it may be necessary.
References
Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav. 2012;62:263-271.
Aghaeepour N, Ganio EA, Mcilwain D, et al. An immune clock of human pregnancy. Science Immunology 2017; 2 (15): eaan2946
Pazos M, Sperling RS, Moran TM, Kraus TA. The influence of pregnancy on systemic immunity. Immunol Res. 2012;54:254-261.
Ledan S Infectious Diseases in Pregnancy. US Pharm. 2020;45(9):22-26.
Arora N, Sadovsky Y, Dermody TS, Coyne CB. Microbial Vertical Transmission during Human Pregnancy. Cell Host Microbe. 2017;21(5):561-567.
Racicot K, Mor G. Risks associated with viral infections during pregnancy. J Clin Invest. 2017;127(15):1591-1599.
Pastoret PP, Henroteaux M. Epigenetic transmission of feline infectious peritonitis. Comp Immunol Microbiol Infect Dis. 1978;1:67-70.
Addie DD, Jarrett O. A study of naturally occurring feline coronavirus infection in kittens. Vet Rec, 1992; 130: 133–137.
Addie DD, Jarrett O. Feline coronavirus infections. In: Greene CE, editor. Infectious diseases of the dog and cat. WB Saunders; Philadelphia: 1990. pp. 300– 312.
Read about diseases that are often confused with FIP. Free continuation of the article on differential diagnoses of FIP.
Toxoplasmosis
Transmission / epidemiology: Obtained by vertical transfer (in young cats) or by hunting or eating raw meat Clinical symptoms: Cats may have involvement of the liver, lungs, nervous system, muscles and / or pancreas. Symptoms include lethargy, anorexia, dyspnoea (pneumonia and / or pleural effusion), jaundice, abdominal discharge, uveitis (especially posterior) and / or neurological symptoms Diagnostic examination: Clinical toxoplasmosis is less common than FIP and is usually not associated with severe hyperglobulinemia or a decreased albumin / globulin ratio, which often occurs in FIP. Hyperbilirubinaemia may occur. Serology (high IgM titer or rising IgG titer) may be useful in diagnosis. The organisms can be found by sampling and microscopic examination of, for example, the lung or lymph nodes. PCR can also be performed on such samples to detect the presence of Toxoplasma gondii DNA. In cases with neurological symptoms, cerebrospinal fluid (CSF) PCR may be performed. Treatment: If toxoplasmosis is suspected, trial treatment with clindamycin may be initiated to determine if a positive reaction occurs.
Lymphocytic cholangitis (LC)
Epidemiology: It has been thought that Persian cats may be predisposed to the disease, but recent studies have not confirmed the predisposition to this breed. Clinical signs: Often associated with jaundice. Some cats with LC have abdominal discharge Diagnostic examination: The nature of the effusion is similar in terms of protein concentration to FIP (i.e. high), although the number of cells in LC is usually higher than the number observed in FIP. Hyperglobulinemia can also be observed in LC. Both LC and FIP cases can be hyperbilirubinemic. In contrast to FIP, LC is also usually associated with a marked increase in liver enzymes, especially cholestatic markers (i.e., alkaline phosphatase and gamma-glutamyltransferase), compared to the milder or moderate increase that occurs in FIP cats. Furthermore, cats with LC are usually not as ill as those with FIP; for example, they may be polyphagic rather than anorexic
Neoplasia (eg lymphoma, abdominal cancer)
Epidemiology: Lymphoma can affect young cats, but occurs in cats of all ages. Older cats usually have additional neoplasms. Focal lesions of FIP in the gut or (especially mesenteric) lymph nodes can manifest themselves very similarly to cases with apparently solitary neoplasms of these organs. Clinical symptoms: Lymphoma can affect multiple body organs and, like FIP, can lead to lymphadenopathy and / or biquavian effusions. Cats are often systemically ill Diagnostic examination: Sampling of affected tissues or effusions followed by cytology may confirm the diagnosis of lymphoma rather than mixed inflammatory cells, which usually occur in cytological sampling of FlP-affected tissues. Other neoplastic lesions (eg carcinomas) can be diagnosed by effusion cytology
Pancreatitis
Clinical symptoms: Cats may experience anorexia, jaundice and weight loss. Severe fever is not a common symptom, although it can occur in cases of acute pancreatitis that are associated with severe pain and / or sepsis. Diagnostic examination: Hyperbilirubinaemia may occur. In acute cases, a small amount of abdominal fluid is sometimes present (usually with high protein and high cell counts [non-degenerate neutrophils], as opposed to high protein and low cell effusion in FIP). Pancreatitis can be diagnosed by ultrasonography and pancreatic measurements. feline pancreatic lipase. Treatment: Trial treatment with antiemetics and analgesics may be used
Retroviral infection
Epidemiology: Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) infections are more common in adults than in young cats, but age-related immunity plays a role in FeLV infection, with younger cats being more susceptible to infection. Both cats are more likely to have external viruses. FeLV affects both males and females, while males have an increased risk of FIV infection. Clinical signs: Both FeLV and FIV infection may be associated with pyrexia, lethargy, lymphadenopathy and / or uveitis. Diagnostic examination: FIV infection can be associated with severe hyperglobulinemia. Please note that retroviral positivity may be a risk factor for the development of FIP
Mycobacterial infection including tuberculosis (TB)
Epidemiology: There are geographical differences in prevalence and infection is usually associated with outdoor access and hunting Clinical symptoms: Lymphadenopathy, respiratory symptoms and / or uveitis, as well as wet non-healing wounds, may occur. Affected cats may be in relatively good condition despite the disease, and pyrexia and anorexia are not common symptoms, although acute manifestations such as shortness of breath may occur. Mycobacterial infections that affect the lungs usually affect the lung parenchyma compared to pleural effusion as in FIP. Diagnostic examination: Mycobacterial infection is usually not associated with the severe hyperglobulinemia or decreased albumin / globulin ratio observed in FIP. Hypercalcaemia may occur. The cytology of the affected lymph nodes or organs shows inflammatory changes (marked macrophages, but inflammation may be similar to FIP with pyogranulomatous changes). Ziehl-Neelsen staining of cytology or biopsy specimens may be positive and specimens may be sent for culture (although positive culture results may take up to weeks in slow-growing organisms, and cultivation may be impossible with some mycobacterial species). An interferon gamma test is available, which is performed on blood samples and helps diagnose suspected cases of feline TB.
Pyothorax
Clinical symptoms: It may be associated with pyrexia. Pleural effusion is seen Diagnostic examination: Chest effusion analysis reveals a very high number of cells due to marked neutrophilic inflammation with degenerative changes and the possible presence of intracellular bacteria, although any previous antibiotic treatment may cause the presence of bacteria not to be confirmed. Unique effusion.
Sepsis
It can be associated with many conditions; for example with septic peritonitis, pyothorax, pneumonia, pyelonephritis Clinical symptoms: Pyrexia (although low temperatures may occur in cats), tachycardia or bradycardia, tachypnoea, and other symptoms associated with the source of sepsis may occur in cats. Diagnostic examination: Leukocytosis, neutrophilia and hyperbilirubinaemia (in the absence of increased liver enzymes) may be present.
Septic peritonitis
Clinical symptoms: They may be associated with pyrexia. Presence of abdominal effusion Diagnostic examination: Abdominal effusion analysis reveals a very high number of cells due to marked neutrophilic inflammation with degenerative changes and possibly intracellular bacteria, although any previous antibiotic treatment may cause bacteria not to be detected. Unique effusion. Glucose concentration in abdominal effusion is lower than blood concentration (> 1.1 mmol / l)
Congestive heart failure (CHF)
Clinical symptoms: Bicavitary effusions are possible in the pleural and peritoneal spaces, although pleural effusions are much more common in abdominal CHFs than abdominal effusions, and separate abdominal effusions are very rare in feline CHFs. The presence of gallop, arrhythmia and possibly heart murmur increases the suspected CHF index. Jugular vein distension may be present in right-sided CHF. Diagnostic examination: The fluid is a modified low protein transudate, unlike the fluid observed in FIP. Echocardiography confirms heart disease and CHF.
Rabies
In countries where rabies is endemic, it must be considered a differential diagnosis in unvaccinated cats with neurological symptoms, especially acute behavioral changes and progressive paralysis.
Edited by Tasker S and Dowgray with permission from BSAVA Publications, Gloucester
Basic facts - Feline leukemia virus (FeLV) is a retrovirus related to the murine leukemia virus that existed among feral cats for tens of thousands of years before its discovery in 1964 (Jarrett et al., 1964). FeLV infection occurs mainly in cats less than 3-8 years of age (Pedersen, 1998, 1991). Cats in the asymptomatic stage of the infection are the main source of infection. The virus is secreted in all secretions and bodily secretions and spreads by close contact (Pedersen et al., 1977). FeLV infection usually occurs in nature after cats are old enough to socialize, and the primary phase of the infection is either asymptomatic or transient and ends with a long-lasting immune response in 95% or more cats. Only a small proportion of infections in nature lead to chronic viremia. FeLV-associated diseases occur predominantly in a small group of cats with persistent infection. FeLV disease in feral cats did not arouse increased interest prior to its discovery, and any associated mortality remained unnoticed among the spectrum of diseases that affect feral cats. What we know about the pathogenesis of FeLV infection in feral cats therefore originally came from studies conducted in the 1970s and 1980s on groups of domestic cats and laboratory infections (Review Pedersen, 1998, 1991).
Epizootiology - FeLV appears to have inadvertently migrated from the wild to the domestic cat population sometime before the 1960s, and the incidence has increased rapidly since then. The first indications that the virus may be behind the disease came in 1964 with the identification of intracellular particles resembling the murine leukemia virus in the cat's home with multiple cases of lymphosarcoma (Jarrett et al., 1964). Our understanding of the severity of FeLV infection and its relationship to diseases other than lymphosarcoma began in 1969 in research laboratories (Hardy et al., 1969). The main spectrum of FeLV-related diseases arose from the commercial application of the Indirect Fluorescence Antibody Test (IFA) for the detection of viremic cats, beginning in 1972 (Hardy, 1973; Hardy and Zuckerman, 1991). Rapid domestic ELISA-based FeLV assays followed (Lutz et al., 1979).
FeLV was retrospectively identified as the leading cause of domestic cat disease in the 1960s and prospectively in the 1970s and 1980s. What caused the panzootic of FeLV infection and diseases in domestic cats? It was later found that a human-controlled environment with a large population of cats, especially where young kittens were in contact with older infected kittens and cats, proved to be ideal for cat-to-cat transmission. The severity of these exposures, along with young age (Hoover et al., 1976) and other environmental stressors, has significantly increased the incidence of persistent infections compared to transient infections (Pedersen et al., 1977). While only a small percentage of cats in the wild become permanently viremic, one-third or more cats exposed in a controlled laboratory environment have developed persistent viremia.
The end of the FeLV panzootic came with extensive "testing and segregation" of viremic cats, as documented by Weijer et al. (1986). Testing and segregation were later supplemented by effective vaccines. Remarkably, FeLV infection is no longer the leading cause of disease in households with multiple cats. Again, it exists as a natural infection, with positivity only in 1-5% wild cats. However, several viremic cats, especially younger ones, continue to appear among cats moved from the wild to shelters and temporary homes.
Pathogenesis - primary FeLV infection is largely insignificant in nature and terminated by a strong immune response and lifelong immunity (Review Pedersen, 1991). However, if the extent of exposure is large enough and / or the feline's immunity is reduced in some way, primary and transient disease may occur. This stage can be manifested by fever, generalized lymphadenopathy, low platelet and WBC counts, and mild anemia. This stage is often followed by long-lasting and largely asymptomatic viremia lasting months and years. Cats with persistent FeLV infection eventually develop several primary and secondary diseases, which are usually fatal. The usual mortality estimate for viremic cats is around 50% per year (Pedersen, 1988), which means that only 12.5% of them will survive after three years. Because infection in nature occurs mainly in younger cats and most of them die within 3 years, few cases of FeLV infection are observed in nature in cats older than 5-8 years.
Primary FeLV diseases are associated with various mutants of the infecting strain and include aplastic anemia, various myeloproliferative disorders, and lymphoma, which is usually generalized, ocular, or neurological (Summary Pedersen 1988, 1991). FeLV-associated secondary disease is caused by several common feline infectious agents, which are usually not very pathogenic, but which are exacerbated by suppression of FeLV-associated T cell immunity.
Relationship between FeLV and FIP infection – It was found that one-third to one-half of cats with FIP during the 1970s and 1980s were infected with FeLV (Cotter et al., 1973; Pedersen et al., 1977). The association between the two infections was demonstrated when young laboratory cats infected with enzootic feline enteric coronavirus (FECV) were housed with FeLV carriers (Pedersen et al., 1977). When these young cats became persistently infected with FeLV, their coronavirus antibody titers began to rise and within weeks or months clinical signs of FIP appeared. FIP occurred in only one-third of cats with FeLV viremia, and two-thirds of cats that became immune to FeLV did not develop FIP. In a later study, cats chronically infected with a laboratory strain of feline immunodeficiency virus (FIV) were experimentally infected with FECV (Poland et al., 1996). Two of 19 cats in the chronic immunosuppressive stage of FIV infection developed FIP, whereas none of 20 FIV-uninfected “housemates” became ill. Studies similar to this one with immunosuppression of FeLV and FIV were important in concluding that FIP virus (FIPV) was a commonly occurring mutant of FECV and a minimal pathogen in healthy immunocompetent cats.
What does FeLV infection mean for the treatment of FIP? I admit that I am not in favor of FIP treatment in FeLV-positive cats. We know that FeLV infection induces the type of immunosuppression that leads to the development of FIP. I also suspect that successful treatment with FIP antivirals such as GS-441524 is based on restoring the protective immune response to FIPV. If true, FeLV-induced immunosuppression may interfere with FIPV immunity and reduce the cure rate in GS treatment, or interfere with any long-term protective immunity elicited by successful antiviral therapy. Two other problems with the treatment of such cats need to be considered. Breeding FeLV-infected cats causes financial and physical difficulties in terms of routine veterinary care and quarantine of susceptible cats. It is also known that only 10% cats infected with FeLV survive for more than three years. These facts raise questions about the best use of the resources of temporary / rescue groups and individuals - for cats with only FIP, cats with other treatable diseases or for healthy cats waiting for home?
Conclusion - Foster parents / rescuers are unlikely to choose not to treat FIP in FeLV positive cats. However, the decision to treat FIP in such cats must be based primarily on the accuracy of the initial FeLV test. About 5 of the 100 positive in-house FeLV ELISAs in a healthy cat population will be false positive. If FeLV is present in the 1% street cat population, false positive results will be five times more common than true positives. Therefore, it is important that positive ELISAs are confirmed by another test, such as PCR. Owners should, whenever possible, ensure that these cats do not have other FeLV-related diseases, such as aplastic anemia, lymphoma or myeloproliferative disorders. Cat owners who opt for GS treatment should also share the short-term and long-term results of their efforts in order to obtain a better prognosis in this FIP group.
References
Cotter SM, Gillmore CE, Rollins C. 1973. Multiple cases of feline leukemia and feline infectious peritonitis in a household. J Am Vet Med Assoc 162:1054-1058.
Hardy WD Jr., et al. Feline leukemia virus: occurrences of viral antigen in the tissues of cats with lymphosarcoma and other diseases. Science 1969, 166:1019-1021.
Hardy WD Jr. Horizontal transmission of feline leukemia virus in cats. Nature 1973, 244:266269.
Hardy WD Jr., Zuckerman EE. Ten-year study comparing enzyme-linked immunosorbent assay with the immunofluorescent antibody test for detection of feline leukemia virus infection in cats. J Am Vet Med Assoc. 1991, 199:1365-73.
Hoover EA, et al. Feline leukemia virus infection: Age-related variation in response of cats to experimental infection. J Natl Cancer Inst. 1976, 57:365-369.
Jarrett WFH, et al., Leukemia in the cat. A virus-like particle associated with leukemia (lymphosarcoma). Nature 1964, 202:567-56.
Lutz H, et al. The Demonstration of Antibody Specificity by a New Technique. The Gel
Electrophoresis-Derived Enzyme-Linked Immunosorbent Assay (GEDELISA) and its Application to Antibodies Specific for Feline Leukemia Virus. J Histochem Cytochem. 1979, 27: 1216-1218.
Pedersen NC. Feline Infectious Diseases. American Veterinary Publications, Inc., Goleta, CA, USA, 1988.
Pedersen NC. Feline leukemia virus infection. In: Feline Husbandry. Disease and management in the multiple-cat environments. American Veterinary Publications, Inc., Goleta, CA, USA, 1991, pp210-228.
Pedersen NC, Theilen G, Keane MA, Fairbanks L, Mason T, Orser B, Che CH, Allison C. 1977. Studies of naturally transmitted feline leukemia virus infection. Am J Vet Res 38: 1523–31.
Poland AM, Vennema H, Foley JE, Pedersen NC. 1996. Two related strains of feline infectious peritonitis virus isolated from immunocompromised cats infected with feline enteric coronavirus. J Clin Micro 34: 3180–3844. Weijer K, de Haag U, Osterhaus A. 1986. Control of feline leukemia virus infection by a removal program. Vet Rec, 119, 555–556.
The use of supplements for dogs and cats is becoming more common, which reflects the trend of using supplements for humans. I have also noticed that many cat owners use numerous supplements to support the treatment of FIP with GS-441524. I strongly feel that these supplements have no effect and cost the owners a huge amount of money. Some owners decide to take the supplements themselves, but in some cases they use them on the advice of their veterinarians. People also rely on supplements in those parts of the world where there is a lack of veterinary care. In many cases, they are "prescribed" to prevent, slow down or reverse specific medical conditions. In fact, they are often used just to do something, and even if they don't work, at least they don't hurt. In some cases, it is sufficient to indicate that a particular authority "needs some form of assistance". A significant proportion of test panels performed even in healthy animals will show one or more suspicious values, especially in the blood, liver or kidneys. Such values should not be used as a reason for prescribing or selling supplements. As a person who believes in scientific methods and clinical trials aimed at ensuring safety and efficacy, I cannot in good conscience recommend owners to use untested over-the-counter supplements that they claim to prevent, alleviate or treat diseases.
I am aware of the many testimonies that exist on the web that prove the effectiveness of a wide range of products. However, there are also many articles from reputable sources that support my beliefs. I quote excerpts from such articles below.
"Much has been written about the nutritional supplements business, the billions of dollars-long industry with strong political ties, and the deplorable inadequacy of regulation, which allows for extensive marketing of supplements without a solid scientific basis or scientific evidence. …………. . The marketing used to promote these supplements, of course, goes beyond anything justified by real scientific evidence and is almost generally unreliable. Likewise, testimonies and anecdotes about their effects, whether from patients, pet owners, veterinarians or Nobel laureates, are just stories that have almost no probative value. And since most good medical ideas will not eventually become a real and effective clinical therapy, it is likely that many of these even more attractive products will prove ineffective or cover unknown risks. Without adequate supporting evidence and effective quality control, regulation and post-market surveillance, we can never be sure that by using them, we are helping and not harming our patients. "
"Claims about the effectiveness of many pet supplements and nutraceuticals are often based on subjective evaluation methods, including owner reviews, when they have not been rigorously tested in well-designed clinical trials and published in professional journals and should therefore be viewed with skepticism. Although the results extrapolated from studies performed in humans or rodent models are valuable for interspecies comparisons, they do not take into account the different pharmacokinetics and pharmacodynamics of different species. Furthermore, many pet supplements and nutraceuticals are consumed orally, and the bioavailability of orally administered drugs varies greatly between species. Consumers should also be advised to be skeptical of in vitro test-based marketing claims. For example, many of the declared benefits of joint supplements for pets are based on in vitro tests, which often rely on very high doses applied directly to cartilage explants or cultured chondrocytes. "
As far as animals are concerned, the Food and Drug Administration (FDA), the Center for Veterinary Medicine (CVM) in the United States, regulates two classes of products: food and medicine. Depending on the intended use, the animal nutritional supplement is considered to be a food or medicine. There is no separate category for "supplements" for animals.
The Health Supplements Act (DSHEA) of 1994 defined the term 'food supplement', but did not specify whether the definition applied to humans, animals or both. The main benefit of DSHEA has been the reclassification of certain regulated food ingredients into food additives that require approval before being placed on the market.
In 1996, CVM published a notice in the Federal Register explaining that DSHEA did not apply to animal products.
Federal laws and regulations simply do not know the category of animal products called "nutritional supplements." Depending on the intended use, the product is either a food or a drug regulated by the FDA.
Many owners buy products for their pets for human use. It is important to know that manufacturers of human nutritional supplements may not provide the FDA with evidence that their supplements are effective or safe. However, they are not allowed (knowingly) to place dangerous or ineffective products on the market.
As soon as a nutritional supplement is placed on the market, the FDA must prove that the product is not safe in order to limit or withdraw it from the market.
On the contrary, before manufacturers can get a drug on the market, they must obtain FDA approval by providing convincing evidence that it is safe and effective.
Some supplements that are safe for humans can be toxic to dogs or cats. Therefore, it is essential that pet owners consult their veterinarians before administering the supplement to their pet.
Russia has registered the world's first coronavirus vaccine for dogs, cats, minks, foxes and other animals, the local agricultural supervisory authority said on Wednesday.
The vaccine, called Carnivak-Cov, was developed by scientists from the Federal Service for Veterinary and Phytosanitary Surveillance, also known as Rosselkhoznadzor, the Russian agency Tass News reported.
Since many scientists claim that the virus that caused Covid-19 originally jumped from the bat to humans, or even through another intermediary, infections in animals, from zoos to mink farms, have been reported around the world.
It remains unclear how easily the virus can be transmitted between animals and humans. However, after repeated infections among minks on farms in Denmark and elsewhere in Europe, millions of fur animals were killed as a precaution to prevent possible transmission. The researchers were particularly concerned about possible mutated variants of the virus developed in minks and other animals that could infect humans.
Russia has already conditionally approved three coronavirus vaccines for human use. Rosselkhoznadzor's deputy head, Konstantin Savenkov, said on Wednesday that it would be the first approved vaccine in the world for a wide range of animal vaccinations.
The vaccine could be mass-produced in April, although the agency did not say when it would be available on the market. It will be produced by the Russian Federal Center for Animal Health, which is the largest producer of veterinary products in Russia.
"Carnivak-Cov, a sorbate-inactivated coronavirus infection vaccine," is the first and only product in the world to prevent Covid-19 in animals, "Savenkov told Tass News.
Two U.S. companies, a New Jersey-based veterinary pharmaceutical company, Zoetis and Medgene Labs of South Dakota, are also developing coronavirus vaccines for use in minks and other animals.
Russian researchers launched clinical trials in October 2020, and tested the vaccine on dogs, cats, minks and foxes, as well as polar foxes, among other animals. According to Savenko, mass production of the vaccine could begin in April 2021.
"The research results give us reason to assume that the vaccine is safe and has a strong immunogenic effect," Savenkov said.
The vaccine is expected to develop antibody resistance that will last for at least six months.
Savenkov told Tass News that "domestic breeders and trading companies from Greece, Poland and Austria" are planning to buy the vaccine, while companies from the United States, Canada and Singapore have also shown interest in it.
The Russian coronavirus vaccine for human use has not yet been approved in either the United States or Europe.
Earlier this year, Zoetis was given a trial trial of nine infected apes at the San Diego Zoo, who have recovered ever since.
Feline coronavirus (FCoV) is reported worldwide and is known to cause disease in both domestic and non-domesticated feline species. Although FCoV often leads to mild or subclinical disease, a small subset of cats succumb to the deadly systemic disease, feline infectious peritonitis (FIP). The outbreak of FIP in cheetahs (Acinonyx jubatus) in the zoo's collection highlighted the devastating effect of introducing FCoV into a group of animals. In addition to cheetahs, FIP has also been recorded in European wild cats (Felis silvestris), tigers (Panthera tigris), mountain lions (Puma concolor) and lions (Panthera leo). This article provides an overview of reported cases of FIP in non-domesticated cat species and highlights FCoV in non-domesticated cat populations.
Introduction
Infectious diseases pose a significant threat to wildlife conservation.74 Soil fragmentation has the potential to allow higher populations to grow in natural habitats than usual, and urban sprawl may increase the interaction of wild cats with domestic cats.15 Recently, the COVID-19 pandemic also highlighted undelivered felines when the coronavirus SARS-CoV-2 was first detected in a tiger (Panthera tigris) at the Bronx Zoo in New York, NY, with subsequent cases diagnosed in other cats kept in captivity in the same zoo; 122 although the condition of these animals has improved since diagnosis, coronaviruses remain a concern for the health of cats in both domestic and non-domestic environments.
Feline coronavirus infections are currently widespread in the domestic cat population. 17 In most domestic cats, the disease is either asymptomatic or manifests as self-limiting mild diarrhea. 83 However, a small subset of cats experience an "internal mutation" that leads to macrophage tropism46, wherein these cats succumb to a systemic disease known as FIP. 9,60,99 FCoV classified as alpha-coronavirus (species alpha-coronavirus-1) can be divided into two biotypes: benign feline enteric coronavirus or feline infectious peritonitis virus (FIPV).82 Furthermore, the virus can be classified according to serotype as feline coronavirus type I or type II.52 These viral types originally differed based on a different antibody response, but it has recently been proposed that they be considered different genetic strains based on their spike glycoproteins.68 Type II viruses are much less common in natural infections, yet they are more easily isolated and propagated in cell culture systems, and have been characterized in more detail. The type II virus is considered to be derived from double homologous recombination between the native FCoV type and canine coronavirus.46
The viral spike protein is the driving mechanism of cellular tropism and pathogenesis. The FCoV type II receptor is known to be feline aminopeptidase (fAPN), 114 while type I viruses have a different and as yet unknown receptor. 21 Another feature distinguishing between the two virus types is the fusion activation process, the type I virus contains two proteolytic activation points (at sites S1 / S2 and S29), while the type II virus has a single cleavage point S29.52 Although both serotypes are known to cause FIP, many questions remain as to the natural behavior of each and the host's response to infection.
Location
Year
Seroprevalence
References
South Africa
1977–1978
1.12
51
1982
3.52
8,45
1989
0/40and
105
1999–2001
105/107
57
Serengeti / Tanzania
1985
8.25
8,45
-
24/39
26
Kenya
1985
4.12
8,25,45
Namibia
1999–2001
19/39
57
1992–1998
21/72
72
2002-2004
3/88b
113
Botswana
2008–2011
2.6
11
Winston, Oregon (epidemic)
Before June 1982
0/25
8,45
1983
35/35
8,45
1985
16/16
8,45
North America
1986
31/90
8,45
1987
49/91
8,45
1989
42/102
26
1990
106/164
26
1991
24/39
26
England
1985
1.12
8,25,45
Table 1. FCoV seroprevalence in cheetahs that move freely and in captivity. a) Paired samples of a total of 40 animals (80 samples). b) Repeated sampling has taken place
Antibody responses to both type I and type II FCoV have been reported in captive cats in the United States, with reports specifically reporting a response to FCoV type I in cheetahs, African lions (Panthera leo) and Bengal tigers (Panthera tigris tigris). ), and the response against FCoV type II in cheetahs, jaguars (Panthera onca), African lions, Bengal tigers, lynxes (Lynx canadensis), snow leopards (Panthera uncia) and African leopards (Panthera pardus pardus).56 In some cases, type II FCoV is considered to be more transmissible compared to type I virus in domestic cats, 123 although due to the presence of both types of viruses in the study facility, this could not be confirmed. The situation in feral cats is unknown.
Clinically, there are two classic forms of the disease in cats, namely effusion or non-fusion ("wet" or "dry"). The wet form of FIP is characterized by effusion in the abdominal or thoracic cavity, or both, or in the pericardial cavities, and the dry form by the presence of pyogranulomatous lesions. However, the clinical symptoms associated with the FIPV biotype can be quite variable and non-specific. FCoV and FIP remained a major global challenge. Vaccination is not recommended, in part due to concerns about negative outcomes due to exacerbation of antibody-dependent infection in the presence of non-neutralizing antibodies.125 Despite promising initial studies 73,84 and other treatment options still do not have approved antiviral therapies. Prevention is difficult and pre-mortem diagnosis is challenging. Current PCR and serological testing methodologies do not distinguish between pathological forms of the virus and antibody titers are unpredictable. In feline populations, FCoV secretion is often observed in non-FIP positive animals. Likewise, antibody titers only provide evidence of previous exposure and a negative antibody test in domestic cats does not rule out the possibility of FCoV secretion.29 Depending on the antibody assay, sensitivity and specificity may provide variable assistance in the diagnosis of FIP, as found by Felten and Hartmann.28 Immunohistochemistry (IHC) currently remains the gold standard for the diagnosis of FIP.28 Managing the virus can be problematic in the management of captive species, and limited reference ranges for blood analysis, high stress scenarios, and possible new presentations are uncertain.
FIP and FCoV in non-domesticated species
Cheetah (Acinonyx jubatus): In 1979 Horzinek and Osterhaus51 demonstrated a serological response to FCoV in cheetahs for the first time (Table 1). In 1982, it became clear that cheetahs could suffer from the same serious illness as FCoV-infected domestic cats when a FIP outbreak in captive-bred cheetahs at Winston Zoo, Oregon. 27,88 The first individual (8.5 year old female) was recently introduced into the herd and had non-specific symptoms of the disease including lethargy, anorexia, dehydration, fever and jaundice with hematocrit 30%, hyperproteinemia (9.1 g / dl), leukocytosis and azotemia.88 Ascites was present at post-mortem examination, along with fibrinous lesions adjacent to the abdominal organs and fluid in the thoracic cavity.88 Petechization has been reported in several organs.88 In the months that followed between this initial case and other cases of FIP, occasional diarrhea was observed in other cheetahs.27 Pathology of tissue samples from other animals that died of FIP revealed multifocal necrotic lesions affecting the abdominal organs (liver, kidney, pancreas, spleen), lymph nodes, and thyroid gland. Facial erosions and ulcerative glossitis have also been observed.27 Although it is not possible to rule out calicivirus, which also causes these ulcers, there are a number of recent cases with human patients with COVID-19 who have experienced tongue ulcers due to infection.94 Longitudinal serological monitoring following the first case of cheetah FIP showed seroconversion, and by 1983 each cheetah in the park was serologically positive.6,27,45 During this epidemic, almost 60% cheetahs succumbed to FIP.25,45 Early characterization of the cheetah isolate involved inoculation of several cell lines, including feline Crandall-Rees kidney cells (CRFK), Felis catus-4 fetal cells (FCWF-4), and two kidney-derived cheetah cell lines (AjuKid234) or fibroblasts (AjuFib238).24 CRFK cells showed similar properties after inoculation with cheetah isolates compared to the two FCoV type I strains, while FCWF-4 cells were less permissive to the isolate. Across cheetah cell lines, AjuKid234 cell transmissibility was low.24
Other cases of FIP have also been reported in a litter of three caught, approximately 6-month-old wild cheetahs, co-infected with Toxoplasma gondii.119 Clinical pathology data revealed hypochromic anemia, neutrophilia, lymphopenia and eosinopenia with normal total protein but elevated alpha-2 globulin and gamma globulins.119 In addition to fibrinous peritonitis and lesions affecting the abdominal organs, pulmonary edema and gastric blood have also been reported.119 In this report, the authors point to a lack of diet; however, other predisposing factors may include relocation stress and genetic predisposition.119 In a pathological study of 31 dead cheetahs kept in captivity in North America, the FIP was considered the cause of death in two animals.71 Although FIP was undeniably considered a fatal disease in domestic cats, many hypotheses have been considered that have made cheetahs particularly susceptible to FIP, including genetic control of the immune response, especially the homogeneity of the majority histocompatibility complex (MHC). 25,79 Analysis of the cheetah-infected virus showed deletion mutations in gene 7a, although interestingly, genes 7a and 7b were intact in cheetahs with FIP.58 Since the first recorded case of cheetah FIP, the disease remains sporadic despite evidence of exposure. No further devastating losses have been observed since the initial outbreaks of the FIP epidemic in cheetahs, although research continues.
Following the outbreak of FIP in Oregon, FCoV monitoring revealed a common antibody response to the virus (Table 1). Initial tests have shown that faecal excretion and antibody titers are often inconsistent.45 In a study of farmed and wild South African cheetahs, an overall seroprevalence of 57% (169/298) was observed compared to 36% (66/182) in those who secreted the viral antigen, as assessed by nested reverse transcription polymerase chain reaction (RT / nCR). .57 In 49 animals that shed viral antigen, 46 showed an antibody response against FCoV type I, 45 showed an antibody response against FCoV type II, and three showed no antibody response.57 Whether this high seroprevalence against both type I and II FCoV was caused by a number of circulating viruses, cross-reactivity, or other factors remains unknown, but this finding is unique. In South African cheetahs that were observed longitudinally (n¼48), almost a fifth (n¼10) excreted antigen at more than one time point, even after a negative test after a positive test.57 In serological research, Munson et al. in Namibia72 were more seropositive males, with 5/14 (36%) juvenile males showing seroprevalence compared to 0/8 juvenile females and 13/37 (35%) adult males compared to 3/13 (23%) adult females.
Lifestyle and risk factors for wild and captive species may vary depending on the disease. In a study among captive cheetahs in the United States, three of the 22 healthy cheetahs shed viral antigen (RT / nPCR) (Table 2).55 Of the three viral antigen shedding animals, one animal was positive for anti-FCoV type I antibodies and the other two were seronegative.55 In another 19 animals, the antibody response was determined in 15 animals, of which 10 showed no antibodies, four animals were seropositive against type I virus and one animal was seropositive against both type I and type II viruses.55 However, in another study on 10 cheetahs that did not shed the virus, the antibodies were common against type II virus (5/10) compared to type I (4/10) or both (1/10). Discrepancies in the response of specific antibodies may be due to changes in management strategies, seasonal fluctuations, or differences in sample handling. In addition, the differences between the antibody response and faecal excretion pose a challenge to the actual disease state of the animal, both in captive cheetahs and in wild cheetahs. To provide guidance on the testing strategy, faecal samples were collected from 25 cheetahs in captivity in the United States for 30 days.38 Of these faecal samples, viral antigen was found in 13% (4/31 samples) fecal samples from one animal to 93% (26/28 samples) samples from one animal.38
Common name
Genus species
Antigen frequency
References
European wild cat
Felis silvestris
5/15
44
African wild cat
Felis lybica
0/2
57
Black-footed cat
Felis nigripes
0/1
57
American cougar
Puma concolor
0/20
37
Jaguarundi cat
Puma yagouaroundi
0/16
37
0/1
43
Cheetah
Acinonyx jubatus
22/90
45
66/182
57
3/22
55
Bengal cat
Prionailurus bengalensis
3/34
12
Spanish lynx
Lynx pardinus
0/25
67
0/68
65
Lynx
Lynx lynx
0/2
102
Ocelot
Leopardus pardalis
0/8
43
0/21
37
0/1and
62
Margay
Leopardus wiedii
0/14
43
0/7
37
Pampas cat
Leopardus colocolo
0/22
37
Small-spotted cat
Leopardus [Oncifelis] geoffroyi
0/1
43
0/6
37
Ocelot tree
Leopardus tigrinus
0/24
37
0/20
43
Rys caracal
Caracal caracal
0/2
57
African lion
Panthera leo
0/1
57
American Jaguar
Panthera onca
0/61
37
Spotted leopard
Panthera pardus
0/2
57
Table 2. Detection of FCoV antigen in non-domesticated cats. (a) part of the diagnostic test
The role of persistent cheetah infections in the development of ulcerative colitis and other long-term consequences remains relatively unclear and represents a potential area for study.96,112 In 1993 Munson71 described in two dead cheetahs with lesions characteristic of FIP also pathological changes in the villi of the small intestine in one animal (FIP did not consider the cause of death in even one cheetah). In a sample of nine cheetahs with necrotizing colitis and diarrhea that ruled out FCoV, six animals showed antibodies only to FCoV type I, two animals showed antibodies to both type I and type II, and one animal was not positive for antibodies of any serotype.56 Furthermore, FCoV was diagnosed in cheetah pups showing acute hind limb paresis, but no apparent relationship to serology was demonstrated, and antibody titers varied from animal to animal during testing.120,121 Feline leukoencephalomyelopathy (LFL) in large cats has been identified in many cheetahs and two other feline species in the United States. The disease is characterized by progressive vision loss, disorientation and difficulty eating.7 In the process of understanding the etiology of LFL, 14 animals were tested immunohistochemically for FCoV, but no animals in this small subgroup showed positive.7
European wild cat (Felis silvestris): In 1993, Watt and colleagues124 reported an outbreak of FIP in European feral cats in a closed colony that had existed for almost 14 years and affected only males. Numerous clinical signs have been reported, along with multisystem organ involvement, including liver, kidney, intestine, brain, lung, heart, and lymphatic tissue.124 Respiratory symptoms were noted in two cats.124 It has not been established how cats became infected and it is considered unlikely that a stray cat could introduce the virus. Whether the source of the contamination could have been the nurse or the nurses at the zoo was not further investigated. It was also not determined whether there was long-term shedding of the virus. Interestingly, a previous study by McOrist et al.64 was unable to identify European feral kittens as serologically positive for FCoV exposure by indirect immunofluorescence assay (IFA) performed on plasma and directed against the Wellcome virus strain (Table 3). Most recently, however, Heddergott et al.44 reported 47.1% (16/34) seroprevalence in a sample of 34 European wild cats in Luxembourg and found that increasing age was a predictor of antibody status. Of the 16 seropositive cats, 75% were seropositive for at least one other common feline viral infection (feline leukemia virus, feline parvovirus, feline calicivirus, or feline herpesvirus).44 Paradoxically, another group of European feral cats was seronegative in Portugal (0/26), although a third (5/15) of faecal samples were positive for viral antigen (Tables 2, 3).19 Differences in sampling and processing may explain some inconsistencies; Possible additional differences include interactions with domestic and other felines and the nature of FCoV infections.
Location
Year
Seroprevalence
References
European wild cat (Felis silvestris), Scotland
1987–1989
0/23
64
1992–1997
3/49
14
France
1996–1997
2/51
61
Luxembourg
2001–2016
16/34
44
Portugal
1992–2007
0/26
19
American Puma (Puma concolor), USA
1978–1991
4/21 (IFA) vs 0/32 (KELA)
97a
1987–1990
16/58
81
1990–2004
25 / 180b
4
2005-2008
0/9
77
1990–2008
74/480
33
Brazil
Unknown
3/5
103
1998–2004
0/18
30
Canada
1996–2001
0/15
89
African lion (Panthera leo), Botswana
2003-2005
0/21
91
1992–2000
16 / 146b
1
2008–2011
0/14
11
2012–2014
0/13
63
Namibia
1991–2001
5/223
1
1999–2001
16/98
57
South Africa
1987–1990
0/32
106
1992–2000
43/312
1
Tanzania
1984–1991
177 / 311c
47
Uganda
1997–1999
0/14
18
Zimbabwe
1990–1998
0/41
1
Germany
1989
0 / 1d
116
Table 3. Seroprevalence in non - domesticated cat species by country and year. a) Felis concolor coryi. b) Estimate from the bar graph presented in the study. c) Repeated sampling. d) Part of the diagnostic examination. IFA uno immunofluorescence test; KELA ¼ Kinetic enzyme-linked immunosorbent assay.
American Puma (Puma concolor): A case of FIP has been reported in a young male American cougar, moving freely in California, who, in addition to enlarged lymph nodes, also had lesions in the small and large intestine, heart, lungs and brain. Interestingly, the kidneys appeared histologically normal, but viral RNA was evident.108 This case report is unique in demonstrating FIP in a free-moving animal, especially in a species that often lives alone. The risk of further cases of FIP in free-ranging bombs remains unknown and other pathogens, such as the zoonotic disease Yersinia pseudotuberculosis, have been reported in bombs with pyogranulomatous liver lesions and peritonitis.3
According to serological research in California bombs, seroprevalence appears to fluctuate during the 18 years during which samples were taken.33 In 1992, only three samples were taken, but one animal was positive, while in the next 3 years no animal was positive (n ¼46). By 1996, seroprevalence began to rise and peaked in 2000–2001, and after another period of decline, the highest seroprevalence reached almost 50% (n ¼ 29).33 Longitudinal data provided by Foley et al.33 are important because previous years do not predict future seroprevalence. An additional study in the Rocky Mountains demonstrates a high degree of correlation between antibody levels in females and their pups, even when the pups were 4 months of age or older at the time of sampling.4 In addition, statistical modeling suggests that increasing age and population location are risk factors for FCoV exposure.4 Other seroprevalences have been reported in the United States (Table 3).
Tiger (Panthera tigris): FIP was reported in an 8-year-old male tiger in captivity in Romania, which initially showed non-specific clinical signs.49 The postmortem examination corresponded to FIP and revealed uveitis, abdominal discharge and, in addition to pericarditis, serous fluid in the pericardial space.49 Macrophage staining for FIP was consistent with the diagnosis, with infected macrophages being identified in the lung and other tissues.49 Amyloid deposits have also been reported.49 There was an increase in serum amyloid A in cats with FIP, potentially similar to human patients with SARS-CoV-2,39,69 Interestingly, amyloidosis is often observed in black-legged cats (Felis nigripes); thus, there may be other host factors that lead to the presence of amyloid plaques in the tiger.111 Finally, in a tiger with FIP, liquefied necrosis was detected in the spleen, although this may not be specific for FIP infection.49
In addition to the described case of FIP in tigers, one case of peritonitis in tigers was recorded in a survey of Italian zoos between 2004 and 2015; however, whether it was related to FCoV infection has not been established and is unlikely.101 A compilation of mortality data on captive-bred tigers in India identified peritonitis in addition to enteritis, gastritis, gastroenteritis, hepatitis and gastric ulcers.107 Although no viral etiology has been reported, gastrointestinal diseases have been one of the most common causes of mortality, even during the monsoon season.107
In Siberian or Amur tigers (Panthera tigris altaica), 43% animals (n-44) were positive for the presence of FCoV antibodies (Table 4).42 Neither sex nor age was associated with seroprevalence, although longitudinal monitoring led to three other tigers becoming seropositive.42 In one case report of a Siberian tiger that succumbed to a morbillivirus infection, IFA demonstrated the presence of anti-FCoV antibodies, although this was unlikely to have contributed to the animal's death.90 In the case report of an captured Amur tiger, which was originally presented with anorexia and lethargy, the IFA was negative for FCoV; further diagnosis revealed bacterial pyothorax.104 Virus shedding was observed in another Siberian tiger considered clinically healthy, but no antibody response.56
Of the three Bengal tigers housed in the same institution, two showed antibody responses to both type I and type II FCoV, and the third showed anti-type II antibodies, although none of these animals secreted viral antigen.56
Lion (Panthera leo): In 1970, Colby reported two cases of FIP in lions.13 Although this initial report did not provide any clinical details, the ocular form of FIP in a 15-year-old captive lion was recently described and confirmed to be blind.75 The patient's clinical pathology, including anisocytosis and hypochromasia, was non-specific for FIP, although PCV (HCT) was lower than normal (31%) and total plasma protein was higher than normal (7.8 g / dl), values commonly found in domestic Histopathology revealed bilateral panuveitis and retinal detachment along with an infiltrate of lymphocytes, plasma cells and several macrophages.75 In the anterior chamber, the exudate was characterized as eosinophilic and proteinaceous, and lesions were found in the brain.75
In free-ranging lions in East Africa, 57% serum samples were evaluated as evidence of an antibody response by IFA (Table 3). 47 FCoV secretion was previously observed in the captive African lion, but without an antibody response.56 Similarly, two other lions in different institutions did not actively secrete the virus, but showed antibody responses.56,57 Interestingly, one of these lions showed a low-level antibody response to both type I and type II FCoV.56. In the case of a series of lions with encephalitis, one lion was tested for antibodies to FCoV, but appeared negative.116 In a study of inbred lions compared to an outbred population, the relationship between inbreed status and FCoV antibodies was not statistically significant.115 A longitudinal study of lions in the Serengeti showed a high degree of seroprevalence variability each year, especially in younger animals.80 In addition, these data revealed possible effects on fertility and a possible link between the spread of the virus and higher population densities.80 The second longitudinal study showed a high degree of seroprevalence; in most age groups more than 50% animals demonstrated seroprevalence and a trend of increasing seroprevalence with increasing age, with a few exceptions34 (additional data from the study). In addition, FCoV seroprevalence may predict the occurrence of calicivirus or feline immunodeficiency virus (FIV).34
Common name
Genus species
Seroprevalence
References
Desert cat
Felis margarita
0/1
51
Manul
Otocolobus manul
0/3
76
0/6and
59
Amur cat
Prionailurus bengalensis euptilura
0/1
51
0/2
41
Iriomote cat
Prionailurus bengalensis iriomotensis
14/17
70
Flat-faced cat
Prionailurus planiceps
0/1
51
Jaguarundi
Puma yagouaroundi
0/1
31
0/1
103
Ocelot
Leopardus pardalis
1/1
103
1/1
30
0/10
31
0/12
35
Margay
Leopardus wiedii
0/1
51
4/4
103
Pampas cat
Leopardus colocolo
1/1
103
Pampas cat
Leopardus geoffroyi
0/9
31
1/40
118
Ocelot tree
Leopardus tigrinus
0/2
30
Rys caracal
Caracal
2/2
57
3/3
113
Serval
Leptailurus serval
0/2
51
Jaguar
Panthera onca
3/4
103
Spotted leopard
Panthera pardus
0/1
51
1/2
57
0/7
113
0/4
11
Sumatrian tiger
Panthera tigris sondaica
0/1
51
Ussuri Tiger
Panthera tigris altaica
19/44
42
Snow leopard
Panthera uncia
0/2b
32
Table 4. Seroprevalence in other non-domesticated cat species. (a) Immunodeficient animals from the Zoo. b) Part of a diagnostic run that involved two paired samples.
Serval (Leptailurus serval): Juan-Salle´sa et al.54 report two FIP cases in a group of four coexisting servers. Case 1, a two-year-old male, stopped entering the indoor area where the animals were routinely fed. It was not determined whether the cause was neurological behavioral changes or anorexia. Case 2 was an 8-year-old female with a melengesterol acetate implant, with non-specific clinical signs and mild abdominal distension.54 Exploratory laparotomy revealed abdominal effusion and FIP-like lesions, and clinical pathology demonstrated leukocytosis and anemia. Although no extensive lesions were reported in Case 1, histology revealed fibrinopurulent ventriculitis; accumulation of neutrophils, fibrin and macrophages in the brain; and severe leptomeningitis. Focal pyogranulomatous lesions were present in the kidneys.54 In case 2, in addition to pyogranulomatous necrotizing splenitis, pyogranulomatous lesions were also present in the mesentery, liver and gallbladder.54
Feature: VanRensburg and Silkstone119 mention personal communication about FIP that has affected at least one red lynx. Of the 25 red lynx in the Golden Gate National Recreation Area near San Francisco, California, the only urban red lynx was serologically positive for FCoV (Table 5).95 FCoV secretion was reported in two captive red lynx in the US Zoo, despite the absence of an antibody response.56 Similarly, in the second US zoological collection, one healthy feature in captivity secreted FCoV in the absence of an antibody response, while the other trait did not secrete virus but showed a low-level antibody response against FCoV type II.56
The Spanish lynx (Lynx pardinus) was once considered one of the most endangered wild carnivores, and as such, the risks of FCoV infection could be devastating. In one study of 22 Spanish traits evaluated by competitive enzyme-linked immunosorbent assay (ELISA) and 25 animals evaluated by IFA or rapid immunochromography, no animals showed signs of exposure or active FCoV infection.67. However, further studies have shown a seroprevalence of approximately 26%, with no apparent relationship between FCoV and FeLV.65 In a single sample of the Spanish lynx, 19/74 were positive for FCoV IFA exposure, although 0/68 animals shed virus in the faeces, as assessed by RT-PCR.65 In two other lynx features for which the cause of death could not be determined, neither animal was found to be IHC positive for FCoV, despite pancreatitis and fibrinous serositis in one of these animals.102 The effect of FCoV on the development of other disease pathologies, including membrane glomerulonephritis and lymphoid cell depletion, has also been investigated, but no study has shown an apparent link to disease development.53,86
Kind of
Location
Year
Seroprevalence
References
Spanish Lynx (Lynx pardinus)
Spain
1989–2000
0/37
98
2003-2007
19/74
65
2004-2006
0/22
67
Lynx lynx
Netherlands
1977–1978
0/1
51
Sweden
1993–1999
0/102
100
Canadian Lynx (Lynx canadensis)
North America
1993–2001
12/215
5
Canada
2000
0/5
89and
Red Lynx (Lynx rufus)
USA
1992–1995
1/25
95
Unknown
0/1b
87
Table 5. FCoV seroprevalence by lynx species species. (a) Listed as a feature. b) Part of diagnostic processing.
Leopard (Panthera pardus): FIP has also been reported in leopards in Germany.117 No exclusion of FCoV was observed in three African leopards at two US zoos, but all three were serologically positive for type II FCoV.56 Of the other two African leopards in South Africa, only one animal was seropositive and none shed the virus (Tables 2, 4).57
Bengal wild cat (Prionailurus bengalensis): Between 2005 and 2006, 35 of a total of 1,453 rectal swab specimens obtained from Asian leopard cats in wildlife markets were positive for the new coronavirus, which found that the spike protein was phylogenetically similar to the spike protein of other alpha-coraviruses.16 However, this virus showed a phylogenetic relationship outside the group, suggesting that it separated at the beginning of the coronavirus evolutionary history, or probably represented an unidentified group of coronaviruses. Recent analysis suggests that the spike protein is related to a newly identified genus of deltacoronavirus.110 According to previously published results of an RT seminested PCR assay targeting viral polymerase, 8.8% (3/34) wild Bengal cats were positive for pancoronavirus, with a close phylogenetic relationship to FCoV.12 In Iriomote cats, subspecies (Prionailurus bengalensis iriomotensis), most animals (14/17) tested by ELISA against canine coronaviruses showed the presence of antibody (Tables 2, 4).70
Clouded Leopard (Neofelis nebulosa): In a survey of the causes of mortality of non-domesticated carnivores at Nandankanan Biological Park in Bhubaneswar, Orissa, India, peritonitis was thought to be the cause of death in one clouded leopard; 92 however, FCoV has not been studied.
Snow Leopard (Panthera uncia): FCoV secretion was observed in a healthy captive snow leopard, although no antibody response was evident.56 In contrast, virus excretion was not observed in two snow leopards at different institutions, but were positive for antibodies to FCoV type II. 56 In the case report of a 6-week-old captured bred male snow leopard with neurological disease, including cerebellar degeneration and encephalomyelopathy, FCoV was investigated as a potential cause, but was not identified.109
Ocelot (Leopardus pardalis): Philoni et al.30 reported one seropositive, caught, apparently healthy Amazonian ocelot, which was also serologically positive for feline herpesvirus1, feline calicivirus, feline parvovirus and Bartonella henselae. This single observation may have been an anomaly and the result of other underlying medical conditions. Interestingly, however, the anti-B. henselae antibody response was associated with the anti-FCoV antibody in domestic cats.40 It is not known whether a similar association exists for ocelots or other cats. Natural FCoV circulation in isolated ocelots nevertheless appears to be rare (Tables 2, 4).31,35
Swamp cat (Felis chaus): In a survey of non-domesticated feline carnivores in Nandankanan Biological Park, peritonitis was thought to be the cause of death in one jungle cat; 92 however, FCoV has not been studied.
American Jaguar (Panthera onca): FIP was considered a differential diagnosis in a case report of a newborn jaguar with respiratory difficulties that progressed to ascites.36 However, the confirmatory diagnosis did not take place and the pup recovered after extensive treatment.36 In two apparently healthy jaguars in captivity, FCoV secretion was observed; in addition, one of these animals showed an antibody response to FCoV type II. (Tables 2, 4)56
Caracal caracal: Four caracals showed an antibody response, although none animal excreted FCoV (Tables 2, 4).56,57
Discussion
In addition to other infectious diseases, feline coronavirus challenges the effort to preserve non-domesticated felines.74 Credible FIP records exist for seven non-domesticated species of felines and 15 species have shown seroprevalence. However, antigen release is observed relatively rarely. Screening and diagnostic testing are challenging and it is still difficult to determine the source of FCoV infection. In the cases reported by Watt et al.124 and Juan-Salle et al., 54 it was considered unlikely that the stray cat would be the source of the infection. Whether the virus was constantly circulating in these animals, or whether the virus was introduced in any other way, remains unknown. This leads to the need to always be vigilant with regard to biosecurity, especially in the case of endangered animals. The use of faeces to identify FCoV creates a strategy for easy sampling of both wild and captive animals; however, PCR from fecal contents may be inhibited.20 In addition, treacherous onset in some cases of FIP often requires an investigation of the potential or exposure to FCoV infection. The spectrum of clinical manifestations, in addition to the "standard clinical picture", also includes dermatological lesions, 10,93 myocarditis 22 and upper respiratory tract diseases.2
Reports of FIP outbreaks in non-domestic cats have shown that males are likely to be at higher risk than females, similar to those observed in domestic cats. FIP has only been found in European wild male cats, and through individual reports we know of FIP in mountain lion, lion and tiger, which only affected males. 49,75,108, 124 In domestic cats, males are also over-represented in FIP cases.78 In addition, in humans, SARSCoV-2 infection led to more serious consequences in men compared to women.66
While shelters and kennels are the optimal place for FCoV to spread, FCoV circulation in free-moving species can be improved by the solitary lifestyle of some of these species. The virus survives in the environment for a relatively short time, so that the transmission takes place mainly through direct or indirect interactions within the species or with other felines. In some cases, domestic cats can be a source of prey for larger non-domesticated felines. It is not known whether an infection could occur in this way, but it could be the cause of certain antibody responses or antigen secretion in the feces. Habitat changes, including fragmentation and habitat expansion, may, in addition to exposing domestic cats, lead to increased interactions within the same species in the wild.
Although antibody testing is useful for detecting previous exposure, even in non-domesticated species, a seronegative assay does not always indicate the absence of virus shedding.38,56 This discrepancy poses a challenge to understanding the true levels of FCoV circulating in feral cat populations. Several testing strategies have demonstrated the ability to detect virus shedding with a high degree of reliability, including the feasible possibility of obtaining five samples in a row.38 Taking into account critically endangered species, individuals must be adequately tested before being introduced to individuals of the same species, together with stress minimization, unnecessary anesthesia, etc. Sequential testing of faecal samples has been performed in captive animals, and similar strategies may be useful for understanding the presence or absence of FCoV in wild animal populations.
Acknowledgments: The authors greatly appreciate the members of the Whittaker Lab and the Cheetah Conservation Fund for their helpful discussion in preparing this manuscript. Jobs Dr. Stouta is supported by the National Institutes of Health comparative medicine training program (T32OD011000). The work in the author's laboratory (GRW) is partly funded by the Cornell Feline Health Center and the Winn Feline Foundation.
References
Alexander KA, McNutt JW, Briggs MB, StandersPE, Funston P, Hemson G, Keet D, van Vuuren M. Multi-host pathogens and carnivore management in southern Africa. Comp Immunol Microbiol Infect Dis. 2010; 33 (3): 249–265.
Andre´ NM, Miller AD, Whittaker GR. Feline infectious peritonitis virus-associated rhinitis in a cat. J Feline Med Surg Open Rep. 2020; 6 (1): 1–6.
Bernard JM, Newkirk KM, McRee AE, Whittemore JC, Ramsay EC. Hepatic lesions in 90 captive nondomestic felids presented for autopsy. Vet Pathol. 2015; 52 (2): 369–376.
Biek R, Ruth TK, Murphy KM, Anderson CR, Johnson M, DeSimone R, Gray R, Hornocker MG, Gillin CM, Poss M. Factors associated with pathogen seroprevalence and infection in rocky mountain cougars. J Wildl Dis. 2006; 42 (3): 606–615.
Biek R, Zarnke RL, Gillin C, Wild M, Squires JR, Poss M. Serological survey for viral and bacterial infections in western populations of Canada lynx (Lynx canadensis). J Wildl Dis. 2002; 38 (4): 840–845.
Briggs MB, Evermann JF, McKeirnan AJ. Felineinfectious peritonitis: an update of a captive cheetah population. Feline Pract. 1986; 16 (2): 13–16.
Brower AI, Munson L, Radcliffe RW, Citino SB, Lackey LB, Van Winkle TJ, Stalis I, Terio KA, Summers BA, de Lahunta A. Leukoencephalomyelopathyof mature captive cheetahs and other large felids: a novel neurodegenerative disease that came and went? Vet Pathol. 2014; 51 (5): 1013–1021.
Brown EW, Olmsted RA, Martenson JS, O'BrienSJ. Exposure to FIV and FIPV in wild and captive cheetahs. Zoo Biol. 1993; 12 (1): 135-142.
Brown MA, Troyer JL, Pecon-Slattery J, RoelkeME, O'Brien SJ. Genetics and pathogenesis of feline infectious peritonitis virus. Emerg Infect Dis. 2009; 15 (9): 1445–1452.
Cannon MJ, Silkstone MA, Kipar AM. Cutaneous lesions associated with coronavirus-induced vasculitis in a cat with feline infectious peritonitis and concurrent feline immunodeficiency virus infection. J Feline Med Surg. 2005; 7 (4): 233–236.
Chaber AL, Cozzi G, Broekhuis F, Hartley R, JW McNutt. Serosurvey for selected viral pathogens among sympatric species of the African large predator guild in northern Botswana. J Wildl Dis. 2017; 53 (1): 170–175.
Chen CC, Chang AM, Chen WJ, Chang PJ, Lai YC, Lee HH. Molecular survey for selected viral pathogens in wild leopard cats (Prionailurus bengalensis) in Taiwan with an emphasis on the spatial and temporal dynamics of carnivore protoparvovirus 1. BioRxiv [Internet]. 2020.02.21.960492; doi: https: // doi. org / 10.1101 / 2020.02.21.960492
Daniels MJ, Golder MC, Jarrett O, MacDonaldDW. Feline viruses in wildcats from Scotland. J Wildl Dis. 1999; 35 (1): 121–124.
Daszak P, Cunningham A, Hyatt A. Emerginginfectious diseases of wildlife — threats to biodiversity and human health. Science. 2000; 287 (5452): 443-449.
Dong BQ, Liu W, Fan XH, Vijaykrishna D, TangXC, Gao F, Li LF, Li GJ, Zhang JX, Yang LQ, Poon LLM, Zhang SY, Peiris JSM, Smith GJD, Chen H, Guan Y. Detection of a novel and highly divergent coronavirus from Asian leopard Cats and Chinese ferret badgers in southern China. J Virol. 2007; 81 (13): 6920–6926.
Drechsler Y, Alcaraz A, Bossong FJ, CollissonEW, Diniz PPVP. Feline coronavirus in multicat environments. Vet Clin North Am Small Anim Pract. 2011; 41 (6): 1133–1169.
Driciru M, Siefert L, Prager KC, Dubovi E, Sande R, Princee F, Friday T, Munson L. A serosurvey of viral infections in lions (Panthera leo), from Queen Elizabeth National Park, Uganda. J Wildl Dis. 2006; 42 (3): 667–671.
Duarte A, Fernandes M, Santos N, Tavares L. Virological survey in free-ranging wildcats (Felis silvestris) and feral domestic cats in Portugal. Vet Microbiol. 2012; 158 (3-4): 400-404.
Dye C, Helps CR, Siddell SG. Evaluation of realtime RT-PCR for the quantification of FCoV shedding in the faeces of domestic cats. J Feline Med Surg. 2008; 10 (2-3): 167-174.
Dye C, Temperton N, Siddell SG. Type I felinecoronavirus spike glycoprotein fails to recognize aminopeptidase N as a functional receptor on feline cell lines. J Gen Virol. 2007; 88 (Pt 6): 1753–1760.
Ernandes MA, Cantoni AM, Armando F, Corradi A, Ressel L, Tamborini A. Feline coronavirusassociated myocarditis in a domestic longhair cat. JFMS Open Rep. 2019; 5 (2): 1–5.
Evermann JF, Burns G, Roelke ME, McKeirnanAJ, Greenlee A, Ward AC, Pfeifer ML. Diagnostic features of an epizootic of feline infectious peritonitis in captive cheetahs. In: Proc Am Assoc Vet Lab Diagn; 1983. 26: 365–382.
Evermann JF, Heeney JL, McKeirnan AJ, O'Brien SJ. Comparative features of a coronavirus isolated from a cheetah with feline infectious peritonitis. Virus Res. 1989; 13 (1): 15-27.
Evermann JF, Heeney JL, Roelke ME, McKeirnan AJ, O'Brien SJ. Biological and pathological consequences of feline infectious peritonitis virus infection in the cheetah. Arch Virol. 1988; 102 (3-4): 155-171.
Evermann JF, Laurenson MK, McKeirnan AJ, Caro TM. Infectious disease surveillance in captive and free-living cheetahs: an integral part of the species survival plan. Zoo Biol. 1993; 12 (1): 125-133.
Evermann JF, Roelke ME, Briggs MB. Felinecoronavirus infections of cheetahs: clinical and diagnostic features. Feline Pract. 1986; 16 (3): 21-28.
Felten S, Hartmann K. Diagnosis of felineinfectious peritonitis: a review of the current literature. Viruses. 2019; 11 (11): 1068.
Felten S, Klein-Richers U, Hofmann-LehmannR, Bergmann M, Unterer S, Leutenegger CM, Hartmann K. Correlation of feline coronavirus shedding in feces with coronavirus antibody titer. Pathogens. 2020; 9 (8): 598.
Filoni C, Cata˜o-Dias JL, Bay G, Durigon EL, Jorge RSP, Lutz H, Hofmann-Lehmann R. First evidence of feline herpesvirus, calicivirus, parvovirus, and Ehrlichia exposure in Brazilian Free-ranging felids. J Wildl Dis. 2006; 42 (2): 470–477.
Fiorello CV, Noss AJ, Deem SL, Maffei L, Dubovi EJ. Serosurvey of small carnivores in the Bolivian Chaco. J Wildl Dis. 2007; 43 (3): 551–557.
Fix AS, Riordan DP, Hill HT, Gill MA, EvansMB. Feline panleukopenia virus and subsequent canine distemper virus infection in two snow leopards (Panthera uncia). J Zoo Wildl Med. 1989; 20 (3): 273–281.
Foley JE, Swift P, Fleer KA, Torres S, GirardYA, Johnson CK. Risk factors for exposure to feline pathogens in California mountain lions (Puma concolor). J Wildl Dis. 2013; 49 (2): 279–293.
Fountain-Jones NM, Packer C, Jacquot M, Blanchet FG, Terio K, Craft ME. Endemic infection can shape exposure to novel pathogens: pathogen cooccurrence networks in the Serengeti lions. Ecol Lett. 2019; 22 (6): 904–913.
Franklin SP, Kays RW, Moreno R, TerWee JA, Troyer JL, VandeWoude S. Ocelots on Barro Colorado Island are infected with feline immunodeficiency virus but not other common feline and canine viruses. J Wildl Dis. 2008; 44 (3): 760–765.
Fransen DR. Feline infectious peritonitis in an infantile jaguar. In: Proc Am Assoc Zoo Vet; 1974. 261– 264.
Furtado MM, Taniwaki SA, de Barros IN, Branda˜o PE, Cata˜o-Dias JL, Cavalcanti S, Cullen L, Filoni C, Almeida Ja´como AT de, Jorge RSP, Silva NDS, Silveira L, Ferreira Neto JS . Molecular detection of viral agents in free-ranging and captive neotropical felids in Brazil. J Vet Diagn Invest. 2017; 29 (5): 660– 668.
Gaffney PM, Kennedy M, Terio K, Gardner I, Lothamer C, Coleman K, Munson L. Detection of feline coronavirus in cheetah (Acinonyx jubatus) feces by reverse transcription-nested polymerase chain reaction in cheetahs with variable frequency of viral shedding. J Zoo Wildl Med. 2012; 43 (4): 776–786.
Giordano A, Spagnolo V, Colombo A, PaltrinieriS. Changes in some acute phase protein and immunoglobulin concentrations in cats affected by feline infectious peritonitis or exposed to feline coronavirus infection. Vet J. 2004; 167 (1): 38–44.
Glaus T, Hofmann-Lehmann R, Greene C, Glaus B, Wolfensberger C, Lutz H. Seroprevalence of Bartonella henselae infection and correlation with disease status in cats in Switzerland. J Clin Microbiol. 1997; 35 (11): 2883–2885.
Goncharuk MS, Kerley LL, Naidenko SV, Rozhnov VV. Prevalence of seropositivity to pathogens in small carnivores in adjacent areas of Lazovskii Reserve. Biol Bull Russ Acad Sci. 2012; 39 (8): 708–713.
Goodrich JM, Quigley KS, Lewis JCM, AstafievAA, Slabi EV, Miquelle DG, Smirnov EN, Kerley LL, Armstrong DL, Quigley HB, Hornocker MG. Serosurvey of free-ranging Amur tigers in the Russian Far East. J Wildl Dis. 2012; 48 (1): 186–189.
Guimaraes AMS, Branda˜o PE, Moraes W de, Cubas ZS, Santos LC, Villarreal LYB, Robes RR, Coelho FM, Resende M, Santos RCF, Oliveira RC, Yamaguti M, Marques LM, Neto RL, Buzinhani M, Marques R , Messick JB, Biondo AW, Timenetsky J. Survey of feline leukemia virus and feline coronaviruses in captive neotropical wild felids from southern Brazil. J Zoo Wildl Med. 2009; 40 (2): 360–364.
Heddergott M, Steeb S, Osten-Sacken N, Steinbach P, Schneider S, Pir JP, Mu¨ller F, Pigneur LM, Frantz AC. Serological survey of feline viral pathogens in free-living European wildcats (Felis s. Silvestris) from Luxembourg. Arch Virol. 2018; 163 (11): 3131–3134.
Heeney JL, Evermann JF, McKeirnan AJ, Marker-Kraus L, Roelke ME, Bush M, Wildt DE, Meltzer DG, Colly L, Lukas J. Prevalence and implications of feline coronavirus infections of captive and freeranging cheetahs (Acinonyx jubatus). J Virol. 1990; 64 (5): 1964–1972.
Herrewegh AAPM, Smeenk I, Horzinek MC, Rottier PJM, Groot RJ de. Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. J Virol. Ame Soc Microbiol J. 1998; 72 (5): 4508–4514.
Hofmann-Lehmann R, Fehr D, Grob M, ElgizoliM, Packer C, Martenson JS, O'Brien SJ, Lutz H. Prevalence of antibodies to feline parvovirus, calicivirus, herpesvirus, coronavirus, and immunodeficiency virus and of feline leukemia virus antigen and the interrelationship of these viral infections in freeranging lions in east Africa. Clin Diagn Lab Immunol. 1996; 3 (5): 554–562.
Holzworth J. Some important disorders of cats.Cornell Vet. 1963; 53: 157–160.
Horhogea C, Lazar M. Immunohistochemicalmethods to diagnose atraumatic spleen rupture in feline infectious peritonitis of tiger (Panthera tigris). Rev Chim Buchar. 2017; 68 (5): 1055.
Horzinek MC, Osterhaus AD. The virology andpathogenesis of feline infectious peritonitis. Brief review. Arch Virol. 1979; 59 (1-2): 1-15.
Horzinek MC, Osterhaus ADME. Feline infectious peritonitis: a worldwide serosurvey. Am J Vet Res. 1979; 40 (10): 1487–1492.
Jaimes JA, Millet JK, Stout AE, Andre´ NM, Whittaker GR. A tale of two viruses: the distinct spike glycoproteins of feline coronaviruses. Viruses. 2020; 12 (1): 83.
Jime´nez A, Sa´nchez B, Pe´rez Alenza D, Garcı´a P, Lo´pez JV, Rodriguez A, Mun˜oz A, Martı´nez F, Vargas A, Pen˜a L. Membranous glomerulonephritis in the Iberian lynx (Lynx pardinus). Vet Immunol Immunopathol. 2008; 121 (1–2): 34–43.
Juan-Salle´s C, Domingo M, Herra´ez P, Ferna´ndez A, Segale´s J, Ferna´ndez J. Feline infectious peritonitis in servals (Felis serval). Vet Rec. 1998; 143 (19): 535–536.
Kennedy M, Citino S, Dolorico T, McNabb AH, Moffat AS, Kania S. Detection of feline coronavirus infection in captive cheetahs (Acinonyx jubatus) by polymerase chain reaction. J Zoo Wildl Med. 2001; 32 (1): 25-30.
Kennedy M, Citino S, McNabb AH, Moffatt AS, Gertz K, Kania S. Detection of feline coronavirus in captive Felidae in the USA. J Vet Diagn Invest. 2002; 14 (6): 520–522.
Kennedy M, Kania S, Stylianides E, BertschingerH, Keet D, van Vuuren M. Detection of feline coronavirus infection in southern African nondomestic felids. J Wildl Dis. 2003; 39 (3): 529-535.
Kennedy MA, Moore E, Wilkes RP, Citino SB, Kania SA. Analysis of genetic mutations in the 7a7b open reading frame of coronavirus of cheetahs (Acinonyx jubatus). Am J Vet Res. 2006; 67 (4): 627–632.
Kipar A, Meli ML. Feline infectious peritonitis: still an enigma? Vet Pathol. 2014; 51 (2): 505–526.
Leutenegger CM, Hofmann-Lehmann R, RiolsC, Liberek M, Worel G, Lups P, Fehr D, Hartmann M, Weilenmann P, Lutz H. Viral infections in free-living populations of the European wildcat. J Wildl Dis. 1999; 35 (4): 678–686.
Masot AJ, Gil M, Risco D, Jime´nez OM, Nu´nez˜ JI, Redondo E. Pseudorabies virus infection (Aujeszky's disease) in an Iberian lynx (Lynx pardinus) in Spain: a case report. BMC Vet Res. 2016; 13 (1): 6.
McDermid KR, Snyman A, Verreynne FJ, Carroll JP, Penzhorn BL, Yabsley MJ. Surveillance for viral and parasitic pathogens in a vulnerable African lion (Panthera leo) population in the Northern Tuli Game Reserve, Botswana. J Wildl Dis. 2017; 53 (1): 54–61.
McOrist S, Boid R, Jones TW, Easterbee N, Hubbard AL, Jarrett O. Some viral and protozool diseases in the European wildcat (Felis silvestris). J Wildl Dis. 1991; 27 (4): 693-696.
Meli ML, Cattori V, Martínez F, Lo´pez G, Vargas A, Simo´n MA, Zorrilla I, Mun˜oz A, Palomares F, Lo´pez-Bao JV, Pastor J, Tandon R, Willi B , Hofmann-Lehmann R, Lutz H. Feline leukemia virus and other pathogens as important threats to the survival of the critically endangered Iberian lynx (Lynx pardinus). PLOS ONE. 2009; 4 (3): e4744.
Meng Y, Wu P, Lu W, Liu K, Ma K, Huang L, Cai J, Zhang H, Qin Y, Sun H, Ding W, Gui L, Wu P. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients. PLOS Pathog. 2020; 16 (4): e1008520.
Milla´n J, Candela MG, Palomares F, Cubero MJ, Rodrı´guez A, Barral M, de la Fuente J, Almerı´a S, Leo´n-Vizcaı´no L. Disease threats to the endangered Iberian lynx (Lynx pardinus). Vet J. 2009; 182 (1): 114– 124.
Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015; 202 (2015): 120-134.
Mo XN, Su ZQ, Lei CL, Chen DF, Peng H, Chen RC, Sang L, Wu HK, Li SY. Serum amyloid A is a predictor for prognosis of COVID-19. Respirology. 2020; 25 (7): 764–765.
Mochizuki M, Akuzawa M, Nagatomo H. Serological survey of the Iriomote cat (Felis iriomotensis) in Japan. J Wildl Dis. 1990; 26 (2): 236-245.
Munson L. Diseases of captive cheetahs (Acinonyx jubatus): results of the cheetah research council pathology survey, 1989–1992. Zoo Biol. 1993; 12 (1): 105–124.
Murphy BG, Perron M, Bauer K, Park Y, Eckstrand C, Liepnieks M, Pedersen NC. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol. 2018; 219 (2018): 226–233.
Murray DL, Kapke CA, Evermann JF, FullerTK. Infectious disease and the conservation of freeranging large carnivores. Anim Conserv. 1999; 2 (4): 241–254.
Mwase M, Shimada K, Mumba C, Yabe J, Squarre D, Madarame H. Positive immunolabelling for feline infectious peritonitis in an African lion (Panthera leo) with bilateral panuveitis. J Comp Pathol. 2015; 152 (2-3): 265-268.
Naidenko SV, Pavlova EV, Kirilyuk VE. Detection of seasonal weight loss and a serologic survey of potential pathogens in wild Pallas' cats (Felis [Otocolobus] manul) of the Daurian steppe, Russia. J Wildl Dis. 2014; 50 (2): 188–194.
Nicholson KL, Noon TH, Krausman PR. Serosurvey of mountain lions in southern Arizona. Wildl Soc Bull. 2012; 36 (3): 615–620.
Norris JM, Bosward KL, White JD, Baral RM, Catt MJ, Malik R. Clinicopathological findings associated with feline infectious peritonitis in Sydney, Australia: 42 cases (1990–2002). Aust Vet J. 2005; 83 (11): 666–673.
O'Brien SJ, Roelke ME, Marker L, Newman A, Winkler CA, Meltzer D, Colly L, Evermann JF, Bush M, Wildt DE. Genetic basis for species vulnerability in the cheetah. Science. 1985; 227 (4693): 1428–1434.
Packer C, Altizer S, Appel M, Brown E, Martenson J, O'Brien SJ, Roelke-Parker M, HofmannLehmann R, Lutz H. Viruses of the Serengeti: patterns of infection and mortality in African lions. J Anim Ecol. 1999; 68 (6): 1161–1178.
Paul-Murphy J, Work T, Hunter D, McFie E, Fjelline D. Serologic survey and serum biochemical reference ranges of the free-ranging mountain lion (Felis concolor) in California. J Wildl Dis. 1994; 30 (2): 205-215.
Pedersen NC. A review of feline infectiousperitonitis virus infection: 1963–2008. J Feline Med Surg. 2009; 11 (4): 225–258.
Pedersen NC, Allen CE, Lyons LE. Pathogenesisof feline enteric coronavirus infection. J Feline Med Surg. 2008; 10 (6): 529–541.
Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, Liu H. Efficacy and safety of the nucleoside analog GS-441524 for the treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg. 2019; 21 (4): 271–281.
Pedersen NC, Sato R, Foley JE, Poland AM.Common virus infection in cats, before and after being placed in shelters, with emphasis on feline enteric coronavirus. J Feline Med Surg. 2004; 6 (2): 83–88.
Pen˜a L, Garcia P, Jime´nez MA´, Benito A, Alenza MDP, Sa´nchez B. Histopathological and immunohistochemical findings in lymphoid tissues of the endangered Iberian lynx (Lynx pardinus). Comp Immunol Microbiol Infect Dis. 2006; 29 (2): 114-126.
Persky ME, Jafarey YS, Christoff SE, MaddoxDD, Stowell SA, NortonTM. Tick paralysis in a freeranging bobcat (Lynx rufus). J Am Vet Med Assoc. 2020; 256 (3): 362-364.
Pfeifer ML, Evermann JF, Roelke ME, GallinaAM, Ott RL, McKeirnan AJ. Feline infectious peritonitis in a captive cheetah. J Am Vet Med Assoc. 1983; 183 (11): 1317–1319.
Philippa JDW, Leighton FA, Daoust PY, NielsenO, Pagliarulo M, Schwantje H, Shury T, Van Herwijnen R, Martina BEE, Kuiken T, Van de Bildt MWG, Osterhaus ADME. Antibodies to selected pathogens in free-ranging terrestrial carnivores and marine mammals in Canada. Vet Rec. 2004; 155 (5): 135–140.
Quigley KS, Evermann JF, Leathers CW, Armstrong DL, Goodrich J, Duncan NM, Miquelle DG. Morbillivirus infection in a wild Siberian tiger in the Russian Far East. J Wildl Dis. 2010; 46 (4): 1252–1256.
Ramsauer S, Bay G, Meli M, Hofmann-Lehmann R, Lutz H. Seroprevalence of selected infectious agents in a free-ranging, low-density lion population in the Central Kalahari Game Reserves in Botswana. Clin Vaccine Immunol. 2007; 14 (6): 808–810.
Rao AT, Acharjyo LN. Etiopathology of mortality in Indian lesser cats at Nandankanan Biological Park. Indian Vet J. 1994; 71 (6): 550–553.
Redford T, Al-Dissi AN. Feline infectious peritonitis in a cat presented because of papular skin lesions. Can Vet J. 2019; 60 (2): 183–185.
Riad A, Kassem I, Hockova B, Badrah M, Klugar M. Tongue ulcers associated with SARS-CoV2 infection: a case series. Oral Dis. 2020. doi: 10.1111 / odi.13635
Riley SPD, Foley J, Chomel B. Exposure tofeline and canine pathogens in bobcats and gray foxes in urban and rural zones of a national park in California. J Wildl Dis. 2004; 40 (1): 11-22.
Robert N, Walzer C. Pathological disorders incaptive cheetahs. In: Vargas A, Breitenmoser-Wu¨rsten C, Breitenmoser U (eds.). Iberian Lynx ex situ conservation: an interdisciplinary approach]. Madrid (Spain): Biodiversity Fundation / IUCN Cat Specialist Group; 2009. p. 265–272.
Roelke M, Forrester D, Jacobson E, Kollias G, Scott F, Barr M, Evermann J, Pirtle E. Seroprevalence of infectious disease agents in free-ranging Florida panthers (Felis concolor coryi). J Wildl Dis. 1993; 29 (1): 36-49.
Roelke ME, Johnson WE, Milla´n J, Palomares F, Revilla E, Rodrí´guez A, Calzada J, Ferreras P, Leo´nVizcaı´no L, Delibes M, O'Brien SJ. Exposure to disease agents in the endangered Iberian lynx (Lynx pardinus). Eur J Wildl Res. 2008; 54 (2): 171–178.
Rottier PJM, Nakamura K, Schellen P, VoldersH, Haijema BJ. Acquisition of macrophage tropism during the pathogenesis of feline infectious peritonitis is determined by mutations in the feline coronavirus spike protein. J Virol. 2005; 79 (22): 14122–14130.
Ryser-Degiorgis M, Hofmann-Lehmann R, Leutenegger CM, Segerstad CH, Morner T, Mattsson R, Lutz H. Epizootiologic investigations of selected infectious disease agents in free-ranging Eurasian lynx from Sweden. J Wildl Dis. 2005; 41 (1): 58–66.
Scaglione FE, Biolatti C, Pregel P, Berio E, Cannizzo FT, Biolatti B, Bollo E. A survey on zoo mortality over a 12-year period in Italy. PeerJ. 2019; 7: e6198.
Schmidt-Posthaus H, Breitenmoser-Wu¨rsten C, Posthaus H, Bacciarini L, Breitenmoser U. Causes of mortality in reintroduced Eurasian lynx in Switzerland. J Wildl Dis. 2002; 38 (1): 84–92.
Schmitt AC, Reischak D, Clavac CL, MonforteCHL, Couto FT, Almeida ABPF, Santos DGG, Souza L, Alves C, Vecchi K. life and knowledge of the Pantanal matogrossense region. [Feline leukemia and feline peritonitis virus infection in captive and wildcats from Mato Grosso swamp region]. Acta Sci Vet. 2003; 31 (3): 185-188.
Schrader GM, Whiteside DP, Slater OM, BlackSR. Conservative management of pyothorax in an Amur tiger (Panthera tigris altaica). J Zoo Wildl Med. 2012; 43 (2): 425–429.
Spencer JA. Lack of antibodies to coronaviruses in a captive cheetah (Acinonyx jubatus) population. JS Afr Vet Assoc. 1991; 62 (2): 124–125.
Spencer JA. Survey of antibodies to felineviruses in free-ranging lions. South Afr J Wildl Res, 1991; 21 (2): 59–61.
Srivastav A, Chakrabarty B. Seasonal distribution of deaths of tigers (Panthera tigris) in Indian zoos. Zoos Print J. 2002; 17 (3): 741–743.
Stephenson N, Swift P, Moeller RB, Worth SJ, Foley J. Feline infectious peritonitis in a mountain lion (Puma concolor), California, USA. J Wildl Dis. 2013; 49 (2): 408–412.
Stidworthy MF, Lewis JCM, Penderis J, PalmerAC. Progressive encephalomyelopathy and cerebellar degeneration in a captive-bred snow leopard (Uncia uncia). Vet Rec. 2008; 162 (16): 522–524.
Stout AE, Andre´ NM, Jaimes JA, Millet JK, Whittaker GR. Coronaviruses in cats and other companion animals: where does SARS-CoV-2 / COVID-19 fit? Vet Microbiol. 2020; 247: 108777. doi: 10.1016 / j. vetmic.2020.108777
Terio KA, O'Brien T, Lamberski N, FamulaTR, Munson L. Amyloidosis in black-footed cats (Felis nigripes). Vet Pathol. 2008; 45 (3): 393–400.
Terio KA, Walzer ME, Schmidt-Kuntzel A, Marker L, Citino S. Diseases impacting captive and free-ranging cheetahs. In: Marker L, Boast, LK, Schmidt-Kuntzel A. Cheetahs: biology and conservation. Biodiversity of the world: conservation from genes to landscapes. Cambridge (MA): Academic Press; 2018. p. 349–364.
Thalwitzer S, Wachter B, Robert N, Wibbelt G, Mu¨ller T, Lonzer J, Meli ML, Bay G, Hofer H, Lutz H. Seroprevalences to viral pathogens in free-ranging and captive cheetahs (Acinonyx jubatus) on Namibian farmland . Clin Vaccine Immunol. 2010; 17 (2): 232–238.
114. Tresnan DB, Levis R, Holmes KV. Feline aminopeptidase N serves as a receptor for feline, canine, porcine, and human coronaviruses in serogroup I. J Virol. 1996; 70 (12): 8669-8674.
Trinkel M, Cooper D, Packer C, Slotow R. Inbreeding depression increases susceptibility to bovine tuberculosis in lions: an experimental test using an inbred-outbred contrast through translocation. J Wildl Dis. 2011; 47 (3): 494–500.
Truyen U, Stockhofe-Zurwieden N, KaadenOR, Pohlenz J. A case report: encephalitis in lions. Pathological and virological findings. Dtsch Tierarztl Wochenschr. 1990; 97 (2): 89-91.
Tuch K, Witte KH, Wu¨ller H. Feststellung der Felinen Infektio¨sen Peritonitis (FIP) bei Hauskatzen und Leoparden v Deutschland [Determination of feline infectious peritonitis (FIP) in domestic cats and leopards in Germany]. J Vet Med B Infect Dis Vet Public Health. 1974; 21 (6): 426–441.
Uhart MM, Rago MV, Marull CA, Ferreyra Hdel V, Pereira JA. Exposure to selected pathogens in Geoffroy's cats and domestic carnivores from central Argentina. J Wildl Dis. 2012; 48 (4): 899–909.
Van Rensburg IB, Silkstone MA. Concomitantfeline infectious peritonitis and toxoplasmosis in a cheetah (Acinonyx jubatus). JS Afr Vet Assoc. 1984; 55 (4): 205–207.
Walzer C, Ku¨bber-Heiss A, Gelbmann W, Suchy A, Weissenblo¨ck H. Acute hind limb paresis in Cheetah (Acinonyx jubatus) cubs. In: Proc Eur Assoc Zoo Wildl Vet; 1998. p. 267–274.
Walzer C, Url A, Robert N, Ku¨bber-Heiss A, Nowotny N, Schmidt P. Idiopathic acute onset myelopathy in cheetah (Acinonyx jubatus) cubs. J Zoo Wildl Med. 2003; 34 (1): 36–46.
Wang L, Mitchell PK, Calle PP, Bartlett SL, McAloose D, Killian ML, Yuan F, Fang Y, Goodman LB, Fredrickson R, Elvinger F, Terio K, Franzen K, Stuber T, Diel DG, Torchetti MK. Complete genome sequence of SARS-CoV-2 in a tiger from a US zoological collection. Microbiol Resour Announc. 2020; 9 (22): e00468-20.
Wang Y, Su B, Hsieh L, Chueh L. An outbreacof feline infectious peritonitis in a Taiwanese shelter: molecular and epidemiological evidence for horizontal transmission of a novel type II feline coronavirus. Vet Res. 2013; 44 (1): 57.
Watt NJ, MacIntyre NJ, McOrist S. An extended outbreak of infectious peritonitis in a closed colony of European wildcats (Felis silvestris). J Comp Pathol. 1993; 108 (1): 73–79.
Weiss RC, Scott FW. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis. 1981; 4 (2): 175-189.
Zook BC, King NW, Robison RL, McCombs HL. Ultrastructural evidence for the viral etiology of feline infectious peritonitis. Pathol Vet. 1968; 5 (1): 91-95.
Feline infectious peritonitis (FIP) infection is a highly pathogenic and fatal systemic inflammatory disease of cats. Although FIP infection is associated with the immune system, there are several predisposing factors for the disease. FIP has a high degree of interaction with other infectious agents. Feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) infections play a predisposing role by reducing immunity to FIP. This study was performed with Turkish Van cats, a cat breed specific to the Turkish Lake Van region, between 2014 and 2015. Ascites and signs of organ damage in 15 Van cats were identified by pathological analysis at Van Yüzüncü Yıl University. Polymerase chain reaction (PCR) was used to examine the presence of FIV and FeLV in the homogenate of brain, lung, liver, kidney, spleen and intestinal samples with lesions. FIV was identified in 1 (6.7%) of 15 cats and all cat samples were positive for FeLV (100%). Phylogenetic analysis of the positive samples revealed that it was endogenous FeLV. In the FIV phylogenetic analysis, our study strain was found to belong to the FIV subgroup B. The fact that FIP-positive cats were also positive for FeLV has drawn attention to the pathogenesis of endogenous-FeLV in malignancies, which has not yet been understood. In particular, it was concluded that the prevalence of FIP infection can be reduced by paying attention to the vaccination of young cats with FIV and FeLV in environments with a high cat population.
Introduction
Feline infectious peritonitis (FIP) is a fatal disease caused by the feline infectious peritonitis virus (FIPV), which is the result of a coronavirus mutation (FCoV). While FCoV has an enteric form, FIPV is a pathogenic type with a systemic infection. The dramatic increase in the cat population after World War II and the subsequent placement of cats in shelters paved the way for the most important scenario of the FIP. FCoV is thought to spread in the cat population due to their mass concentration, leading to mutant FIPV [1, 2]. Although the disease is not common in older cats, FIP infection is one of the leading causes of death in young cats aged 3 to 24 months. There are two types of FIP: effusive (wet) and granulomatous (dry). While the wet form is the most common and takes the form of inflammatory exudate in body cavities, the granulomatous form attacks the organs [1, 3]. The hypothesis of FIP is based on the fact that viral replication in cats with FCoV occurs in enterocytes. However, another variant of FIPV that can replicate in macrophages due to a mutation in the FCoV genome has also been published. [4]. FIP is a slow, progressive disease and can last for weeks or months. However, retroviral opportunistic infections such as feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV), which cause immunosuppression, lead to the inevitable death by reduced immunity to FIP and accelerated disease. Although cats overcome FIP infection, secondary FeLV and FIV infection reactivates FIPV and dies in a short time. [4-6].
The Retroviridae family, which includes immune-suppressing viruses such as FIV and FeLV, has a linear, single-stranded, non-segmented, genome with a positive RNA polarity of 8-13 kb. Retroviruses that are morphologically enveloped and have icosahedral symmetry contain gag, pol and envelope gene regions [7, 8].
The immune system plays an important role in the clinical manifestations of FIP (wet / granulomatous). In granulomatous cases (dry FIP), T-cell mediated cellular immunity and humoral immunity are key. In FeLV infections in particular, FeLV infection affects the clinic of FIP infection due to disruption of this immune system mechanism. [9]. In addition, cats with FIP infection in the form of a latent or limited infection may experience re-infection due to FeLV. This will again result in death due to the FIP [5]. FIV infection is one of the most important co-infection factors in FIP outbreaks in cats with FCoV. It is reported that FCoV can achieve a very high rate of replication in immunosuppressed cats due to FIV infection, and that this may be a predisposing factor for FCoV to FIPV mutation. In cats infected with FIV and FCoV, FIV causes a high degree of FCoV replication and may lead to an outbreak of FIP in a short time. [1]. These retroviruses, which disrupt the immune system, are the most important clinical indicators of FCoV mutation. [1]. In the case of FIP-induced immune suppression, the transmission of opportunistic pathogens such as FIV / FeLV may occur. [10, 11]. Although there are currently commercial vaccines against FIV and FeLV, there is no protective vaccination or effective treatment against FIP in Turkey. [12].
This study was conducted to determine the interactions between FIPV infection and retrovirus co-infection (FIV / FeLV) in Van cats, a cat breed originating in Turkey.
Materials and methods
The population for the study consisted of a total of 15 cats with suspected FIP, which were transported to Van Yüzüncü Yıl University between 2014 and 2015 for pathological analysis of the death of the Turkish Van cat breed. Refrigerated tissue samples from the brain, lungs, liver, kidneys, spleen and intestines were sent refrigerated to a virology laboratory. For histopathological examinations, tissue samples from all tissues were taken into 10% formalin solution. After 48 hours of fixation in formalin solution, the samples were washed with running tap water for 10 hours. After passing through alcohol (70 °, 80 °, 90 °, 96 ° and 100 °) and xylene, they were immersed in paraffin blocks. Four thick sections were taken from each block to prepare slides on a slide. For histopathological examination, they were stained with hematoxylin-eosin (HE) and examined by light microscopy.
Immunohistochemical examination
All sections taken into adhesion (poly-L-lysine) immunoperoxidase slides were passed through xylene and alcohol series for deparaffinization and dehydration. They were then washed for 5 minutes in distilled water, 5 minutes with phosphate buffer (PBS, pH 7.2) and the endogenous peroxidase was inactivated by standing in 3% H202 for 3 minutes. After washing for 5-10 minutes in PBS, they were incubated for 5 minutes with Protein Block, which is compatible with all primary and secondary antibodies, to prevent non-specific staining of the substrate. At the end of the incubation, the excess blocking solution remaining on the tissue sections was removed and drops of primary antibodies (VGEF, caspase 3, caspase 8, caspase 9, PCNA, neuronectin, TRPM 1, TRPM 2, α synuclein, apelin) and PBS in the control group were used without washing. In accordance with the primary antibody, they were left to stand overnight at +4°C. After washing twice for 5 min. with PBS, they were incubated for 10-30 min. at room temperature with biotinylated secondary antibody. Sections washed again with PBS were left to stand in streptavidin-peroxidase for 10-30 minutes, then washed in the same manner with PBS. After washing, 3-3 'diaminobenzidine (DAB) chromogen was added to the sections and the mixture was left to stand for 5-10 minutes. according to the uptake of the chromogen. After immersion in Mayer's hematoxylin for 1-2 minutes for staining, they were rinsed with running water. They were then passed through an alcohol and xylene series, covered with coverslips and examined with a light microscope (Leica DM 1000). The sections were scored as negative (-), mild (+), moderate (++) and severe (+++) positive according to their immunopositivity.
Investigation of retroviral infections in FIP positive cats
For FIV and FeLV DNA testing of FIP-positive cats, liver, spleen, kidney and brain tissue samples with lesions were taken according to pathological analysis. These tissue samples were combined to prepare a homogenate. Nucleic acid isolation was performed using a supernatant from this tissue homogenate using a commercial kit (GF-1 Nucleic Acid Extraction Kits, Vivantis, Malaysia). The resulting nucleic acid suspension was used as a template for PCR for FIV and FeLV analysis. For FIV DNA screening, nested-PCR was performed using primer pairs specific for the V3-V6 region of the env gene (Table 1). [13]. For FeLV detection, PCR was performed using primer pairs specific for the FeLV env gene region [14]. The primer sequences and product sizes are listed in Table 1.
Example
5′-3 ′ sequence
Polarity
Specificity
Size (bp)
Env Fw
TAY TGG GCC TGT AAC ACY G
+
FeLV
508
Env Rv
CGC TGT TTT AGT CTT TCT CTT A
–
FeLV
VE1S
GAG TAG ATA CWT GGT TRC AAG
+
FIV
1211
VE1R
CAT CCT AAT TCT TGC ATA GC
–
FIV
nVE2S
CAA AAT GTG GAT GGT GGA AY
+
FIV
859
nVE2R
ACC ATT CCW ATA GCA GTR GC
–
FIV
Table 1: Details of oligonucleotides used in the study
Sequential and phylogenetic analysis
After gel electrophoresis, FIV / FeLV positive PCR products were subjected to sequence analysis. The raw data obtained after sequencing were confirmed by GenBank (NCBI National Center for Biotechnology Information / BLAST). Sequences of reference strains and studied samples were arranged by BioEdit program (version 7.0.5) [15]. Phylogenetic analysis was performed using the MEGA program (version 6.0) by the neighborhood method [16].
The results
Pathological findings
At necropsy, gray-white granulomatous lesions in the spleen, liver, kidneys, intestines, lungs and cerebral organs and serous atrophy were observed macroscopically in adipose tissue (Figure 1). In the effusion form, the mucous membranes were found to be strongly icteric and there was a discharge of 1-1.5 l in the abdominal cavity (Figure 2).
Figure 1: Non-fusion form, pyogranulomas clearly visible in seroses of liver, spleen and intestine
Figure 2: Efusion form, approximately 1.5 l of effusion fluid in the abdominal cavity
Microscopic examination revealed, especially in the non-fusible form, pyogranulomatous lesions, necrotic in the middle, spleen, liver, kidneys, intestines, lungs and brain tissues, surrounded by neutrophils, macrophages, lymphocytes and plasma cells (Figure 3). Vasculitis was found in the vessels in these organs (Figure 4). While these granules were generally observed near the serosa, some of them progressed to parenchymal tissue, especially in the kidneys.
Figure 3: Liver, pyogranuloma and mononuclear cell infiltrations consisting of neurophilic leukocytes and mostly with necrotic mass in the middle; H&E, Molding: 50 µm
Figure 4: Renal tissue, FIP positive in tubular epithelium and interstitial intermittent macrophages, IHC-P, Rail: 100 µm
Virological findings
FIV / FeLV DNA was examined by molecular methods in 15 Van cats with FIP diagnosed by pathological analysis. As a result of PCR analysis, FeLV DNA was detected in all 15 cats (100%). In the phylogenetic analysis of FeLV strains in our study and GenBank reference strains, FeLV strains formed two phylogenetic groups: exogenous and endogenous. Sheep and horse retroviruses have been used as a non-member group. In phylogeny, it was observed that all our study strains coalesced together with endogenous FeLV (enFeLV) (Figure 5).
Figure 5: Phylogenetic tree based on the 508 bp nucleotide sequence of 15 FeLV strains generated by Neighbor-Joining using MEGA 6.0 software. Equine and ovine retroviruses were used as a non-member group. Round symbols (•) indicate Turkish tribes
PCR analysis identified FIV in 1 (6.7%) from 15 samples. Subsequently, a sequential reaction and phylogenetic analysis of the FIV strain was performed. Phylogenetic analysis of the FIV strain obtained from our study and reference strains from GenBank showed that the FIV strains were divided into 6 different subtypes from A to F. Our FIV strain was classified as FIV subtype B along with Turkish and Japanese strains (Figure 6).
Figure 6: Phylogenetic tree based on the 859 bp nucleotide sequence of FIV strains generated by Neighbor-Joining using MEGA 6.0 software. The square symbol indicates a Turkish tribe
Discussion
FIP is a systemic infection associated with the immune system caused by coronaviruses. This insidious and deadly infection significantly threatens domestic and street cats that share the same environment with humans, and even breeds of protected cats such as Van cats. Eliminating predisposing factors is the first combat strategy against FIP infection, for which there is not yet an effective method of prevention and treatment in Turkey. Of these factors, cleaning, hygiene and negative interaction in ordinary living spaces are important. Immunosuppressive diseases, such as FIV and FeLV, are the most important predisposing factors for the development of FIPV, a mutant form of coronavirus.
In our study, pathological analysis revealed FIP infection in cats of Van, a breed native to Turkey. Subsequently, the presence of FIV and FeLV was examined in tissue samples obtained from these cats.
FeLV and FIV are pathogenic infectious agents that cause immunosuppression mortality in domestic cats. While FIV is similar to human HIV infection, FeLV causes immunosuppressive, neoplastic, and hematopoietic disorders. [17]. Retroviral infections of cats are the most important trigger for FIP infection in cat homes and shelters. Successful results against retroviral infections have been achieved thanks to the aggressive policies of many Western countries, such as the eradication of infections through testing and vaccination. [18]. Although vaccines against FIV / FeLV infections exist in Turkey, an adequate and controlled vaccination program has not yet been established.
In our study, FeLV was detected in all cats with FIP. FeLV is divided into 6 groups: A, B, C, D, E and T. These types, called exogenous FeLV, are responsible for leukemia and tumor formation in cats. Endogenous FeLV (enFeLV) are FeLV sequences transfected into the genome of domestic cats. enFeLV proviruses are found in various organs and tissues and perform translation and transcription. However, due to the lack of essential parts of the viral genome, it cannot become an infectious viral particle. However, infection of a cat with exogenous FeLV (field strain) leads to recombination between the two (endogenous / exogenous) and transforms enFeLV into an infectious virus particle. However, it is still unclear whether enFeLV may be responsible for malignant formations in cats with lymphoma where exogenous strains are not detected. [19].
In our study, FeLV was detected in all tissue suspensions with pathological lesions collected from Van cats. Phylogenetic analysis showed that they were all enFeLV. Although this suggests that enFeLV may mutate and cause malignant formations, there is no information in the literature to support this hypothesis. There are several studies on coronavirus infection of cats in Turkey. In a study by Pratelli et al., FCoV seropositivity was determined in 62% cats living in environments such as shelters. [20]. In a study by Sahna et al. by molecular methods, the rate was identified by FCoV 54% [21]. A study in Turkey identified a rare ocular form of FIP infection in cats [22]. In a retrospective study of FCoV, FIV and FeLV in 169 sick cats in Turkey, seroprevalence ratios were determined to be 37%, 11% and 1% [23]. Similarly, in a study investigating FCoV, FIV and FeLV in chronic gastrointestinal, urinary, symptomatic and healthy cats in Turkey, viral substances were detected in 45.5%, 9.5% and 20.5%, respectively [24]. In our study, one cat was found to be co-infected with FIV and FeLV. In the phylogenetic analysis of the FIV strain identified in our study, it was found to be a subtype group B. In a previous study performed in cats in Turkey, subtype B was identified in parallel with our results. [25]. In a study of FIV and FeLV infections in cats, the incidence rates of FIV and FeLV were found to be 22.3% and 5.8%, respectively. [26]. Because our study was limited to a specific group, a relatively low FIV / FELV rate was achieved.
Conclusions
Eliminating predisposing factors is the first combat strategy against FIP infection, for which a method of prevention and treatment is not yet effective in Turkey. Although there are vaccines against FIV / FeLV infections that are predisposing factors for FIP, an adequate and controlled vaccination program has not yet been established. Due to the increased incidence of FCoV and predisposing factors, vaccination and awareness of cat owners is important in this regard in order to minimize the spread of FIPV. There is a need to establish a national eradication and control policy for agents such as FIPV and FeLV, which prepare the ground for FIPV infection in shelter cats and even in protected cat breeds.
Compliance with ethical standards
Acknowledgement
SY: For a time he worked at Van Yüzüncü Yıl University. At that time, cat samples were obtained. SY: provided cat samples and performed pathological analyzes, HA: performed virological analysis. SY and HA read the whole article and agreed.
Disclosure of conflicts of interest
The authors declare that they are not aware of the conflict of interest.
Declaration of ethical approval
This study was approved by the Ethics Committee of the Veterinary Faculty Unit of Van Yüzüncü Yıl University (Protocol No. 2015/03).
References
Pedersen NC. (2009). A review of feline infectious peritonitis virus infection: 1963-2008. Journal of Feline Medicine and Surgery, 11 (4), 225-258.
Felten S, Weider K, Doenges S, Gruendl S, Matiasek K, Hermanns W, Mueller E, Matiasek L, Fischer A, Weber K, Hirschberger J, Wess G and Hartmann K. (2017). Detection of feline coronavirus spike gene mutations as a tool to diagnose feline infectious peritonitis. Journal of Feline Medicine and Surgery, 19 (4), 321-335.
Riemer F, Kuehner KA, Ritz S, Sauter-Louis C and Hartmann K. (2016). Clinical and laboratory features of cats with feline infectious peritonitis – a retrospective study of 231 confirmed cases (2000-2010). Journal of Feline Medicine and Surgery, 18 (4), 348-356.
Hartmann K. (2017). Feline infectious peritonitis – new developments in pathogenesis, diagnosis, and management. The Thai Journal of Veterinary Medicine, 47, 97-100.
Pedersen NC. (1987). Virologic and immunologic aspects of feline infectious peritonitis virus infection. Advances in Experimental Medicine and Biology, 218, 529-550.
Pedersen N, Evermann J, McKeirnan A and Ott R. (1984). Pathogenicity studies of feline coronavirus isolates 79-1146 and 79-1683. American journal of veterinary research, 45 (12), 2580-2855.
Liu D. (2016). Feline Leukemia Virus. Molecular Detection of Animal Viral Pathogens, First edition. GRC Press. chapter22, 197.
Burmeister T. (2001). Oncogenic retroviruses in animals and humans. Reviews in Medical Virology, 11 (6), 369-380. [9] Hardy WD. (1982). Immunopathology induced by the feline leukemia virus. Springer Seminars in Immunopathology, 5 (1), 75-106.
Cotter SM, Gilmore CE and Rollins C. (1973). Multiple cases of feline leukemia and feline infectious peritonitis in a household. Journal of the American Veterinary Medical Association, 162 (12), 1054-1058.
Lewis CS, Porter E, Matthews D, Kipar A, Tasker S, Helps CR and Siddell SG. (2015). Genotyping coronaviruses associated with feline infectious peritonitis. Journal of General Virology, 96 (6), 1358-1368.
Nishimura Y, Nakamura S, Goto N, Hasegawa T, Pang H, Goto Y, Kato H, Youn HY, Endo Y, Mizuno T, Momoi Y, Ohno K, Watari T, Tsujimoto H and Hasegawa A. (1996). Molecular characterization of feline immunodeficiency virus genome obtained directly from organs of a naturally infected cat with marked neurological symptoms and encephalitis. Archives of virology, 141 (10): 1933-1948.
Ramirez H, Autran M, Garcia MM, Carmona MA, Rodriguez C and Martinez HA. (2016). Genotyping of feline leukemia virus in Mexican housecats. Archives Virology, 161 (4), 1039-1045. Aydin and Yildirim / GSC Biological and Pharmaceutical Sciences 2019, 06 (02), 071–078 78
Hall TA. (1999). BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98 / NT. Nucleic acids symposium series: [London]: Information Retrieval Ltd., c1979-c2000.
Tamura K, Stecher G, Peterson D, Filipski A and Kumar S. (2013). MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Molecular Biology and Evolution, 30 (12), 2725-2729.
Miyazawa T, Ikeda Y, Maeda K, Horimoto T, Tohya Y, Mochizuki M, Vu D, Vu GD, Cu DX, Ono K, Takahashi E and Mikami T. (1998). Seroepidemiological survey of feline retrovirus infections in domestic and leopard cats in northern Vietnam in 1997. Journal of veterinary medical science, 60 (11), 1273-1275.
Weijer K, Uijtde Haag F and Osterhaus A. (1986). Control of feline leukemia virus infection by a removal program. Veterinary Record, 119 (22), 555-556.
Krunic M, Ertl R, Hagen B, Sedlazeck FJ, Hofmann-Lehmann R, von Haeseler A and Klein D. (2015). Decreased expression of endogenous feline leukemia virus in cat lymphomas: a case control study. BMC Veterinary Research, 11, 90.
Pratelli A, Yesilbag K, Siniscalchi M, Yalcm E and Yilmaz Z. (2009). Prevalence of feline coronavirus antibodies in cats in Bursa province, Turkey, by an enzyme-linked immunosorbent assay. Journal of Feline Medicine and Surgery, 11 (10), 881-884.
Can-Sahna K, Soydal Ataseven V, Pinar D and Oguzoglu TC. (2007). The detection of feline coronaviruses in blood samples from cats by mRNA RT-PCR. Journal of Feline Medicine and Surgery, 9 (5), 369-372.
Baydar E, Eroksuz Y, Timurkan MO and Eroksuz H. (2014). Feline infectious peritonitis with distinct ocular involvement in a cat in Turkey. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, 20 (6), 961-965.
Tekelioglu BK, Berriatua E, Turan N, Helps CR, Kocak M and Yilmaz H. (2015). A retrospective clinical and epidemiological study on feline coronavirus (FCoV) in cats in Istanbul, Turkey. Preventive Veterinary Medicine, 119 (1-2), 41-47.
Oğuzoğlu T, Muz D, Timurkan M, Maral N and Gurcan I. (2013). Prevalences of feline coronavirus (FCoV), feline leukemia virus (FeLV), feline immunodeficiency virus (FIV) and feline parvovirus (FPV) among domestic cats in Ankara, Turkey. Veterinary Medical Review, 164 (11), 511-516.
Oguzoglu TC, Timurkan MO, Muz D, Kudu A, Numanbayraktaroglu B, Sadak S and Burgu I. (2010). First molecular characterization of feline immunodeficiency virus in Turkey. Archives of Virology, 155 (11), 1877-1881.
Yilmaz H, Ilgaz A and Harbor DA. (2000). Prevalence of FIV and FeLV infections in cats in Istanbul. Journal of Feline Medicine and Surgery, 2 (1), 69-70.
Contact the author: e-mail: grw7@cornell.edu. 618 Tower Rd., Ithaca NY 14853 USA.
Abstract
COVID-19 caused by SARS-CoV-2 often manifests as a respiratory disease including cough, dyspnoea, fever and olfactory loss. However, other manifestations of the disease occur in many organ systems, at least in part due to vasculitis and endothelitis. COVID-19-associated multisystem inflammatory syndrome in children (MIS-C) has recently been identified as part of SARS-CoV-2 infection. In feline medicine, feline coronavirus is a common pathogen that can lead to a deadly disease called feline peritonitis (FIP). Like human COVID-19, the clinical manifestations of FIP are due in part to coronavirus-induced vasculitis, which can also lead to fatal multisystemic inflammatory syndrome in cats. Studies investigating how feline coronavirus infection can cause disseminated vasculitis in FIP cats will provide new information that may help people understand COVID-19. We strive for a comparative medicine approach to tackling coronavirus diseases.
The COVID-19 pandemic in 2019-2020 is caused by the recently discovered zoonotic beta-coronavirus classified as SARS-CoV-2. COVID-19 often manifests as a respiratory disease manifested by fever, cough, dyspnoea, olfactory loss, headache, and malaise. More severe disease may include acute respiratory distress syndrome (ARDS); however, the disease also appears to affect other organ systems, including the gastrointestinal, central nervous system (CNS), cardiovascular, renal, hepatic, endocrine, dermatological, hematological, and ophthalmic systems.17 These systemic symptoms are thought to be due to viral endothelial cell infection and endothelitis49 leading to vasculitis.5 COVID-19 can be considered both a respiratory disease and a vascular disease, with widespread viral tropism and high transmissibility contributing to the current public health crisis and the differentiation of SARS-CoV-2 from SARS-CoV, despite the receptor (ACE2) common to both viruses.
After studying the history and pathogenesis of feline coronavirus, we see parallels between COVID-19 and feline infectious peritonitis (FIP) with a wide variety across human and feline coronavirus infections, as originally found in SARS.41 Feline coronavirus (FCoV) in cats is generally considered to be an initial gastrointestinal or rarely respiratory infection that results in FIP, a systemic vascular disease with high morbidity and mortality in some animals.46 This feline disease, originally called chronic fibrinous peritonitis, was first described in 1963. 22; shortly afterwards, the etiological agent (causative agent) was recognized as a coronavirus. This disease, now called feline infectious peritonitis (FIP), occurs worldwide, is almost always fatal, and mainly affects young cats (under 2 years of age).28,38 The etiological agent responsible for most cases of FIP is feline coronavirus (FCoV), alpha coronavirus.25 While FCoV transmission and infection are widespread in domestic cats, systemic disease develops in only a small subset of animals (Figure 1). Common to these various forms of the disease is the identification of virus-induced vasculitis.27 This review highlights the similarities between COVID-19 and FIP and opens up opportunities for cooperation between the medical and veterinary communities in the fight against these devastating diseases.
Figure 1: FIP develops only in a subset of infected cats, despite the widespread spread of FCoV. Similarly, according to current knowledge, many cases of SARS-CoV-2 infection are characterized by a mild or asymptomatic course.
Clinical and pathological profile of feline coronavirus infection: parallels with COVID-19
Like COVID-19 in humans, FIP is involved in many manifestations of the disease in cats (Figure 2), which are described as "variably manifested by multiple organ failure, seizures, generalized effusion, or shock."14 The disease is commonly classified in one of two clinical forms, effusive or "wet" (characterized by accumulation of protein effusion mainly in the peritoneal or pleural cavities) and non-fusive or "dry" (characterized by granulomatous lesions in many organs, including the brain).19 A “mixed form” is also considered, in the clinical spectrum of which granulomatous and pyogranulomatous lesions occurring in the serous part of the liver, kidneys and intestines are common. The spectrum of pathologies observed in FIP includes serositis, hepatitis, nephritis, uveitis and chorioretinitis.38,55 Neuropathological manifestations of FIPV in cats include meningitis, meningoencephalitis, ependymitis, and choroidal plexitis with inflammation ranging from lymphoplasma to pyogranulomatous, and often including vasculitis and perivasculitis. Ophthalmic manifestations, including uveitis and chorioretinitis, are also common. Case reports point to associated heart lesions, including myocarditis and fibrinous epicarditis.12,34 Dermatological lesions that are less commonly observed in FIP include erythema, nodules, and papules.4,8,10 In some cases, early respiratory symptoms have been reported8,54 and in some cats, immunostaining identified the virus in the lung parenchyma.27 Our latest laboratory has confirmed the presence of the virus in the upper respiratory tract by immunostaining.1
Figure 2: Vasculitis caused by FCoV infection can affect many body systems. Since the first descriptions in the 1960s, numerous studies have revealed various forms of the disease.
A similar feature in FIP outbreaks and patients with COVID-19 is extensive vascular involvement.3,5,20 In one of the first reports recognizing vascular involvement in FIP cases, four types of lesions were described: “perivascular edema,” “vascular wall degeneration,” “endothelial proliferation,” and “adventitial and/or perivascular infiltration.”20 In 1989, Boudreaux and colleagues described FIP lesions in several cats as "obliterating" vascular walls. Similarly, August concluded in 1984 that "FIP could be more accurately termed feline coronavirus vasculitis."3 As a naturally occurring disease in cats, FIP and FCoV infection provide an opportunity to understand the pathogenesis of SARS-CoV-2, especially with regard to the co-development of vascular manifestations.
Although observations of myocarditis, rhinitis or skin lesions in FIP are rare, they allow comparison with COVID-191,8,12,42. Frostbite-like lesions, a condition colloquially called "COVID-fingers", have been reported in several patients with COVID-19, although the direct association of these manifestations with COVID-19 remains open.30,33 In cats, a similar condition is known as plasma cell subdermatitis and may also be associated with FCoV. Plasma cell pododermatitis manifests as paw inflammation along with the potential for color changes, ulcerations, and cracks.40 In the case of feline subdermatitis, an association with an infectious disease has been suspected.11 In addition to observing similar paw lesions in FCoV-secreting cats, our laboratory has previously identified subdermatitis in cats due to FIP. Although "COVID fingers" and subdermatitis in cats are rare consequences of infection, they further highlight the spectrum of similarities between COVID-19 and FIP.
One of the characteristic symptoms of COVID-19 is anosmia (loss of smell). Also, in most cases of FIP, the onset of anorexia is common.38,53 Although a non-specific clinical symptom that can be attributed to many different causes, anorexia can be attributed to loss of odor perception - an extremely important sensation that drives appetite in cats. While anosmia is difficult to measure in cats, the relationship between olfactory bulb infection and possible spread to the brain by human and feline coronaviruses deserves further evaluation, especially with regard to the neurological manifestations of both diseases.14,29
Immune component of FIP disease
Based on previous observations of complement and immunoglobulin circulation, including immune complexes, FIP is classically characterized as immune-mediated.24,39 In particular, type III hypersensitivity and Arthus-like reactions lead to the development of immune complexes that can build up in the walls of blood vessels, leading to vasculitis. Despite attempts to classify FIP as a type III hypersensitivity reaction, further work by Kipar and colleagues has shown numerous differences.26,27 Type III hypersensitivity has also been studied in patients with COVID-19.43 The importance of FIP as a type IV hypersensitivity reaction with apparent perivascular lesions consisting of T-lymphocytes, granulocytes and a characteristic feature of FIP, macrophage infiltrates, was also evaluated.36 Delayed-type hypersensitivity is observed in cats inoculated intradermally with FCoV, leading to perivascular cellular infiltrates of macrophages, neutrophils and lymphocytes in the absence of immune complexes.52 However, cellular extravasation associated with FIP lesions contributes to endothelial disruption and the inflammatory response that underlies FIP.27 Specifically, antigen (LFA) -1 associated with β2 integrin adhesion molecules and lymphocytes, β1 integrin very late antigen (VLA) -4 and β2 macrophage antigen (Mac-1) have been demonstrated to be increased in peripheral blood leukocytes isolated from cats with FIP.35 Integrins (LFA) -1 and (VLA) -4 play an important role in neutrophil and monocyte migration across the endothelium and are involved in the development of vasculitis in other disease processes,9,47 while (Mac-1) may play an additional role in the development of thrombosis.51 The hypothetical role of endothelitis, which underlies COVID-1949, parallels previous findings on FIP and the resulting acute vasculitis.
The interaction between vascular pathogenesis and hemodynamics has long been known in FIP.53 In addition to peripheral pyogranulomatous lesions, phlebitis, endothelial edema with inflammatory infiltrates of tunica media, thrombophlebitis and thrombosis were observed in cats experimentally infected with FCoV, classical FIP.53 Additionally, thrombocytopenia, anemia, jaundice, decreased clotting factors VII-XII, increased antithrombin III, and prolonged activated partial thromboplastin time, prothrombin time, and thrombin time are observed after experimental infection.7,53 Thus, the end result for some cats with FIP is the development of disseminated intravascular coagulation.7,53 This is in contrast to the course in human patients with JIS, who are often anticoagulated at some point in their hospital stay, and the rare development of DIC in humans is associated with a worse course in COVID-19.48 The fibrin product D-dimer, a DIC marker, has been studied rarely in cats with FIP, but has been increased in two cases - as expected, observations in patients with COVID-19 have shown this.
The development of FIP in a subset of cats, although most FCoV-infected cats undergo only a subclinical phase, is thought to be the result of an initial immune response.37 Strong cell-mediated immunity (CMI) together with humoral immunity is thought to lead to a subclinical course of the disease, while a lack of CMI leads to an effusive form of the disease and partial CMI leads to a dry form of the disease.37 Similarly, with respect to the immune response, multisystem inflammatory syndrome in children (MIS-C), which may be a manifestation of SARS-CoV-2, has recently been described.16which may develop due to a delayed response to interferon or due to an aberrant IgG response promoting disease progression.44 In addition to MIS-C, multisystem inflammatory syndrome in adults (MIS-A) has been described as a result of SARS-CoV-2 exposure.32
Antibody-dependent exacerbation of infection
In the case of SARS-CoV-2, there were concerns about antibody-dependent enhancement (ADE) infection,13 largely based on experience with other human viruses, such as respiratory syncytial virus, influenza and dengue; despite the need for caution, formal evidence linking ADE to COVID-19 clinical outcomes remains insufficient.2 In cats, it is noteworthy that the involvement of ADE in FCoV infection and the development of FIP with antibodies that would provide means for FCoV to gain macrophage entry has long been considered.21 So far, despite several trials, a viable FCoV / FIP vaccine is still not available.45,50 In contrast to these FIP vaccine studies, preliminary immunization results for COVID-19, for example with stabilized spike immunogens, documented neutralizing, not potentiating, antibody responses.23
Perspectives
COVID-19 is a complex and challenging disease in humans, and similarly, FIP is a complex disease in cats with many factors contributing to the outcome of the disease. By analogy with the persisting question in metastatic tumor research, "seed and soil", the availability of immunological, pathological and physiological samples and data on these similarly fatal inflammatory syndromes from two different coronaviruses in their own host species allow testing of structure / function hypotheses in venous vasculitis . In addition, due to the lack of enthusiasm for clinical biopsy of human patients with fulminant COVID-19 and the great difficulty in achieving good preservation of pathological specimens, it will take a very long time to learn more about the presence or absence of coronavirus in human patients at baseline and during their progression. inflammatory phase of COVID-19.
As a naturally occurring disease with many parallels with COVID-19, we think that FIP may help in future COVID-19 research. Both baseline vasculopathy in both FIP and COVID-19 underline the need to think of these diseases as multisystemic rather than organ-specific diseases. Although often considered a key enteric mode of transmission for FCoV, it is clear that the oropharyngus is a robust portal to host entry. Another factor to consider is that SARS-CoV-2 infects cats.15,18 Although not currently considered a serious disease in cats, it is not a robust animal model for COVID-19, The increased rate of SARS-CoV-2 infection in cats and possible FCoV co-infections raise, in addition to the possibility of viral recombination, concerns about the overlap of pathology and clinical manifestations of human and feline coronaviruses with surprisingly similar vascular disease profiles. However, the fact that SARS-CoV-2 naturally infects cats may offer a model for preclinical evaluation of SARS-CoV-2 vaccines. We believe that further studies are needed to investigate how coronaviruses can cause vascular disease in order to eliminate these devastating diseases, and FIP provides a platform for joint clinical trials bridging feline and human medicine.
Financing
AES is supported by the NIH Comparative Medicine Training Program T32OD011000. GRW is funded by NIH grants R01AI135270 and R21AI135373, SCB is funded by NIH grant R01 AI085089. FIP research in the author's laboratories is funded in part by the Winn Feline Foundation and the Cornell Feline Health Center.
Thanks
We thank Andrew Miller, Robert Goggs, Natalie Zatz and Beth Licitra for critical reading of the manuscript and helpful discussion.
Conflict of interests
The authors are not aware of any conflict of interest.
References
André NM, Miller AD, Whittaker GR. 2020. Feline infectious peritonitis virus-associated rhinitis in a cat. Journal of Feline Medicine and Surgery Open Reports 6: 1–6.
Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, Lanzavecchia A, Corti D, Virgin HW. 2020. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature 584: 353363.
August JR. 1984. Feline Infectious Peritonitis: An Immune-Mediated Coronaviral Vasculitis. Veterinary Clinics of North America: Small Animal Practice 14: 971–984.
Bauer BS, Kerr ME, Sandmeyer LS, Grahn BH. 2013. Positive immunostaining for feline infectious peritonitis (FIP) in a Sphinx cat with cutaneous lesions and bilateral panuveitis. Veterinary Ophthalmology 16: 160–163.
Becker RC. 2020. COVID-19-associated vasculitis and vasculopathy. Journal of Thrombosis and Thrombolysis 50: 499-511.
Biezus G, Cristo TG de, Schade MF da S, Ferian PE, Carniel F, Miletti LC, Maciel A da R, Casagrande RA. 2020. Plasma cell subdermatitis associated with feline leukemia virus (FeLV) and concomitant feline immunodeficiency virus (FIV) infection in a cat. Topics in Companion Animal Medicine 41:
https://doi.org/10.1016/j.tcam.2020.100475.
Boudreaux MK, Weiss RC, Cox N, Spano JS.
Evaluation of antithrombin-III activity as a coindicator of disseminated intravascular coagulation in cats with induced feline infectious peritonitis virus infection. American Journal of Veterinary Research 50: 1910–1913.
Cannon MJ, Silkstone MA, Kipar AM. 2005. Cutaneous lesions associated with coronavirusinduced vasculitis in a cat with feline infectious peritonitis and concurrent feline immunodeficiency virus infection. Journal of Feline Medicine and Surgery 7: 233–236.
Coll-Vinent B, Cebrián M, Cid MC, Font C, Esparza J, Juan M, Yagüe J, Urbano-Márquez Á, Grau JM. 1998. Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis & Rheumatism 41: 435–444.
Declercq J, De Bosschere H, Schwarzkopf I, Declercq L. 2008. Papular cutaneous lesions in a cat associated with feline infectious peritonitis. Veterinary Dermatology 19: 255–258.
Diesel A. Image Gallery: Immune-Mediated Skin Diseases. Clinician's Brief [Internet]. 2020 [cited 2020 September 28]. Available from: http://www.cliniciansbrief.com/article/imagegallery-immune-mediated-skin-diseases
Ernandes MA, Cantoni AM, Armando F, Corradi A, Ressel L, Tamborini A. 2019. Feline coronavirus-associated myocarditis in a domestic longhair cat. Journal of Feline Medicine and Surgery Open Reports 5: 1–5.
Eroshenko N, Gill T, Keaveney MK, Church GM, Trevejo JM, Rajaniemi H. 2020. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nature Biotechnology 38: 789–791.
Foley JE, Rand C, Leutenegger C. 2003. Inflammation and changes in cytokine levels in neurological feline infectious peritonitis. Journal of Feline Medicine and Surgery 5: 313–322.
Gaudreault NN, Trujillo JD, Carossino M, Meekins DA, Morozov I, Madden DW, Indran SV, Bold D, Balaraman V, Kwon T, et al. 2020. SARS-CoV-2 infection, disease and transmission in domestic cats. Emerging Microbes and Infections. https://doi.org/10.1080/22221751.2020.1833687.
Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, Roguski K, Wallace B, Prezzato E, Koumans EH, et al. 2020. COVID- 19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020. Morbidity and Mortality Weekly Report 69: 1074–1080.
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, et al. 2020. Extrapulmonary manifestations of COVID-19. Nature Medicine 26: 1017–1032.
Halfmann PJ, Hatta M, Chiba S, Maemura T, Fan S, Takeda M, Kinoshita N, Hattori S, Sakai-Tagawa Y, Iwatsuki-Horimoto K, et al. 2020. Transmission of SARS-CoV-2 in Domestic Cats. New England Journal of Medicine 383: 592594.
Hartmann K. 2005. Feline infectious peritonitis. Veterinary Clinics of North America: Small Animal Practice 35: 39–79.
Hayashi T, Goto N, Takahashi R, Fujiwara K. 1977. Systemic vascular lesions in feline infectious peritonitis. The Japanese Journal of Veterinary Science 39: 365–377.
Hohdatsu T, Yamada M, Tominaga R, Makino K, Kida K, Koyama H. 1998. Antibodydependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus. The Journal of Veterinary Medical Science 60: 49–55.
Holzworth J. 1963. Some important disorders of cats. The Cornell Veterinarian 53: 157–160.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. 2020. An Vaccine mRNA against SARS-CoV-2 - Preliminary Report. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/nejmoa2 022483.
Jacobse-Geels HEL, Horzinek MC. 1983. Expression of Feline Infectious Peritonitis coronavirus antigens on the surface of feline macrophage-like cells. J. Gen. Virol 64: 1859–1866.
Jaimes JA, Millet JK, Stout AE, André NM, Whittaker GR. 2020. A Tale of Two Viruses: The Distinct Spike Glycoproteins of Feline Coronaviruses. Viruses 12: 83. https://doi.org/10.3390/v12010083.
Kipar A, Bellmann S, Kremendahl J, Köhler K, Reinacher M. 1998. Cellular composition, coronavirus antigen expression and production of specific antibodies in lesions in feline infectious peritonitis. Veterinary Immunology and Immunopathology 65: 243–257.
Kipar A, May H, Menger S, Weber M, Leukert W, Reinacher M. 2005. Morphologic features and the development of granulomatous vasculitis in feline infectious peritonitis. Vet Pathol 42: 321–330.
Kipar A, Meli ML. 2014. Feline Infectious Peritonitis: Still an Enigma? Veterinary Pathology 51: 505–526.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology. 2020 June 1; 77: 683–690.
Mazzotta F, Troccoli T, Bonifazi E. 2020. A new vasculitis at the time of COVID-19. European Journal of Pediatric Dermatology 30: 75–78.
Mesquita LP, Hora AS, Siqueira A de, Salvagni FA, Brandão PE, Maiorka PC. 2016. Glial response in the central nervous system of cats with feline infectious peritonitis. Journal of Feline Medicine and Surgery 18: 1023–1030.
Morris SB, Schwartz NG, Patel P, Abbo L, Beauchamps L, Balan S, Lee EH, PanethPollak R, Geevarughese A, Lash MK, et al.
Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March – August 2020. Morbidity and Mortality Weekly Report 69: 1450–1456.
Noakes A, Majoe S. 2020. Understanding the role that 'COVID toe' has in recognizing the potential extent of COVID-19 infections: a case study. Pathogens and Global Health 114: 283–284.
Oliveira LB, Susta L, Rech RR, Howerth EW. 2014. Pathology in practice: Effusive FIP with fibrinous epicarditis in a cat 245: 899–901.
Olyslaegers DAJ, Dedeurwaerder A, Desmarets LMB, Vermeulen BL, Dewerchin HL, Nauwynck HJ. 2013. Altered expression of adhesion molecules on peripheral blood leukocytes in feline infectious peritonitis. Veterinary Microbiology 166: 438–449.
Paltrinieri S, Parodi MC, Cammarata G, Mambretti M. 1998. Type IV hypersensitivity in the pathogenesis of FIPV-induced lesions. Journal of Veterinary Medicine, Series B 45: 151–159.
Pedersen, N. 1983. Feline infectious peritonitis and feline enteric coronavirus infections. Feline Practice 13: 5–20.
Pedersen NC. 2009. A review of feline infectious peritonitis virus infection: 1963-2008. Journal of Feline Medicine and Surgery 11: 225–258.
Pedersen NC, Boyle JF. 1980. Immunologic phenomena in the effusive form of feline infectious peritonitis. American Journal of Veterinary Research 41: 868–876.
Pereira PD, Faustino AMR. 2003. Feline plasma cell podsermatitis: a study of 8 cases. Veterinary Dermatology 14: 333–337.
Perlman S, Netland J. 2009. Coronaviruses postSARS: update on replication and pathogenesis. Nature Reviews Microbiology 7: 439–450.
Redford T, Al-Dissi AN. 2019. Feline infectious peritonitis in a cat presented because of papular skin lesions. The Canadian Veterinary Journal 60: 183–185.
Roncati L, Ligabue G, Fabbiani L, Malagoli C, Gallo G, Lusenti B, Nasillo V, Manenti A, Maiorana A. 2020. Type 3 hypersensitivity in COVID-19 vasculitis. Clinical Immunology 217: 108487. https://doi.org/10.1016/j.clim.2020.108487.
Scott FW, Corapi WV, Olsen CW. 1992. Evaluation of the safety and efficacy of PrimucellFIP vaccine. Feline Health Topics 7: 6–8.
Sykes JE. Feline Coronavirus Infection. In: Canine and Feline Infectious Diseases. Elsevier; 2014. pp. 195–208. Available from: https://linkinghub.elsevier.com/retrieve/pii/B978 143770795300020X
Takeuchi T, Amano K, Sekine H, Koide J, Abe T. 1993. Upregulated expression and function of integrin adhesive receptors in systemic lupus erythematosus patients with vasculitis. The Journal of Clinical Investigation 92: 3008–3016.
Tang N, Li D, Wang X, Sun Z. 2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis 18: 844–847.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. 2020. Endothelial cell infection and endotheliitis in COVID-19. The Lancet 395: 1417–1418.
Vennema H, Groot RJ de, Harbor DA, Dalderup M, Gruffydd-Jones T, Horzinek MC, Spaan WJ. 1990. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. Journal of Virology 64: 1407–1409.
Wang Y, Gao H, Shi C, Erhardt PW, Pavlovsky A, A. Soloviev D, Bledzka K, Ustinov V, Zhu L, Qin J, et al. 2017. Leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIbα. Nature Communications 8: 15559. https://doi.org/10.1038/ncomms15559.
Weiss RC, Cox NR. 1989. Evaluation of immunity to feline infectious peritonitis in cats with cutaneous viral-induced delayed hypersensitivity. Veterinary Immunology and Immunopathology 21: 293–309.
Weiss RC, Dodds WJ, Scott FW. 1980. Disseminated intravascular coagulation in experimentally induced feline infectious peritonitis. American Journal of Veterinary Research 41: 663–671.
Ziółkowska N, Paździor-Czapula K, Lewczuk B, Mikulska-Skupień E, PrzybylskaGornowicz B, Kwiecińska K, Ziółkowski H.
Feline Infectious Peritonitis: Immunohistochemical features of ocular inflammation and the distribution of viral antigens in the structures of the eye. Veterinary Pathology 54: 933–944.
1.12.2020, Translation 1.5.2021 Original Cornell University blog post: FIP Antivirals
Summary
For families living with a diagnosis of feline infectious peritonitis (FIP) and the veterinarians involved in their care, we understand that the decision to use black market treatment for an otherwise necessarily fatal disease is the ethical dilemma of choosing the lesser of the two evils.
Due to concerns about the safety and efficacy of black market GS-441524 counterfeits, combined with the fact that veterinary supervision of such use is full of legal and ethical dilemmas, we cannot currently recommend the use of such treatment.
We strongly warn against the widespread use of antiviral therapy as monotherapy in farms and shelters with endemic feline enteric coronavirus (FECV). Widespread use in these conditions is expected to generate antiviral-resistant FIP strains.
Opinion
We received many questions regarding the use of GS-441524 in the treatment of FIP. Here is a summary of GS-441524 and our position on its current use. Research into the use of this compound was first published by Dr. Niels Pedersen of UC Davis in 2018. Team Dr. Pedersen published a follow-up study documenting the use of GS-441524 in naturally occurring cases of FIP in 2019. The results of both studies were unprecedented with the 100% (10/10) recovery rate reported in experimentally infected cats and the 84% (25/31) recovery rate in naturally infected cats. Owned cured cats reported returning to "near normal" within two weeks of treatment. The fever usually subsided during the first 12-36 hours, accompanied by a return of appetite. The effusions subsided within 10-14 days and the jaundice gradually subsided within 2-4 weeks. The conclusion of the 2019 study proposes an optimized treatment protocol for the use of GS-441624 at a dose of 4.0 mg / kg given as a subcutaneous injection once a day for at least 12 weeks.
Although managing a natural infection has been shown to be more challenging than an experimental infection, most cats in the study have responded to treatment. Dr. Pedersen is a pioneer in the field of FIP research and there is no doubt about the legitimacy of its work. Unfortunately, there are many issues surrounding the current use of GS-441524. Most of these concerns are directly related to the fact that this medicine cannot be legally purchased from a regulated source. In addition to blocking consumers' access to the medicine, it has also blocked research into best practice and marginalized the role of veterinarians in treatment decisions.
GS-441524 is owned by Gilead Sciences, an American biopharmaceutical company focused on the development of antiviral drugs. Gilead provided GS-441624 Dr. Pedersen for use in his 2018 and 2019 studies, but refused to market the drug for use in cats because of his close relationship with another promising antiviral drug, remdesivir. Prior to the SARS-CoV-2 pandemic, remdesivir was tested for the treatment of Ebola. In a story complicated by human drug licensing challenges, Gilead feared that any adverse effects of GS-441524 reported in cats would harm remdesivir in the FDA approval process. The market for veterinary medicines - even as promising as GS-441524 - is negligible compared to a potential human blockbuster. Gilead considered the use of GS-441524 for the treatment of FIP as an unnecessary risk that could harm the chances of remdesivirus success and refused to license it for use in cats.
This created a black market with GS-441524, led by overseas businessmen in an effort to take advantage of the despair caused by the FIP diagnosis. Treatment is expensive, ranging from $ 1,000 to $ 10,000. There is no formal regulation of these suppliers or their products on the black market. Veterinary professionals may be at legal risk if they recommend, dispense or administer these unapproved medicines. This combination of factors can prevent treated cats from receiving optimal care. We understand that FIP is otherwise a deadly disease, so these risks may seem acceptable, but we warn that unregulated use of GS-441524 has the potential to develop antiviral resistance and jeopardize the success of FIP treatment in the future.
GS-441524 is a nucleoside analog. When viral RNA polymerase integrates GS-441524 into the viral genome, the replication mechanism is blocked and transcription is terminated prematurely, making it difficult for the virus to replicate. We know from experience with nucleoside analogues designed to treat HIV that these drugs do not completely suppress viral replication. The use of single-drug therapy leads to the development of resistant strains. Our most successful experience with antiviral therapy includes combination therapies targeting various aspects of viral replication. Such combination therapies lead to excellent viral suppression and reduce the incidence of antiviral resistance.
The oral form of the nucleoside analog GS-441524 is currently marketed as a supplement to support the feline immune response. Preliminary study Dr. Dianne Addie states that this treatment stops the secretion of the original enteric coronavirus, also known as FECV. This work investigates the prophylactic use of a nucleoside analog in a multi-cat environment where cats have a high risk of developing FIP. Although these results appear to be positive at first sight, they are a matter of deep concern due to the development of antiviral resistance. Although there is preventive prophylaxis for people at high risk of contracting HIV, it is important to emphasize that this medicine, known as Truvada, is a combination antiviral treatment. Decades of experience with HIV have shown that monotherapies are much more likely to result in resistant antiviral strains.
Dr. Addie makes a compelling case for involving veterinarians and researchers in the use of new FIP therapies. We would like to add that there is an obligation to discourage any use that would lead to the development of antiviral resistance. According to one-health, both wild and domestic cats appear to be susceptible to SARS-CoV-2. This has implications for both the veterinary and human worlds: coronaviruses are well known for their ability to recombine in susceptible hosts, and there is a possibility that we are entering uncharted territory with the emergence of recombinant viruses generated under selective antiviral pressure.
One of the bright spots in the dark cloud of the SARS-CoV-2 pandemic is that we will probably soon be able to put aside concerns about the use of the GS-441524 from the black market. A close relative, remdesivir, recently obtained FDA approval for use in a pandemic SARS-CoV-2 infection in humans. Now that the main obstacle to licensing has been clarified, we are optimistic that this will pave the way for the legal and scientifically based use of GS-441524 in cats. While initial studies of GS-441524 have proven to be very promising, important research is still needed in the wider field. Initial data on the efficacy of remdesivir for treatment with COVID-19 illustrated better results than those found in the larger study. WHO, where the drug has only a slight effect on the results at best.
With regard to combination therapy, other potential antiviral drugs for FIP are possible, in particular the protease inhibitor GC376 has a completely different mechanism of action and is a promising component of combination therapy. (Although not mentioned here, the GC376 black market is a very similar case to GS-441524.) Research into the treatment of COVID-19 in humans will undoubtedly lead to the development of promising therapies for cats. Dr. Pedersen posted preliminary data about 25 such compounds, some of which have shown potential for combination therapy. While awaiting GS-441524 approval, there will be questions regarding the off-label use of remdesivir in cats. We warn that the effects of drugs on different species can be unpredictable and that laboratory research is needed to determine safety and efficacy parameters.
For families living with a diagnosis of feline infectious peritonitis (FIP) and for the veterinarians involved in their care, we understand that the decision to use black market treatment for an otherwise necessarily fatal disease is the ethical dilemma of choosing the lesser of the two evils. We hope that this statement provides a useful reference framework for the history of GS-441524, while emphasizing the potential of antiviral resistance in its unregulated use. Pedersen posted own comment to use FIP antivirals from the black market, which provides more detailed information on current use strategies. At Whittaker Lab, we are continuing our basic research into the mechanisms that coronaviruses use to expand their cellular tropism in order to better understand the factors that lead to diseases such as FIP and COVID-19. We are committed to working in solidarity with our fellow researchers, veterinarians and cat owners to create a future without FIP.